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Abstract

CELLULAR MECHANISMS BY WHICH ALCOHOL PROMOTES HIV PROTEASE
INHIBITOR-INDUCED HEPATOTOXICITY

Michael Hinton, B.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2019
Major Director: Huiping Zhou
Professor, Department of Microbiology and Immunology
The development of highly-active-antiretroviral therapy(HAART) has allowed
management of HIV and extended the lives of those infected. Alcohol abuse, which is very
common in HIV-1 infected patients, is one of the most important co-morbid risk factors for liver
injury and has been associated with the occurrence of serious metabolic syndrome and
subsequent discontinuation of HAART in HIV patients. We have identified endoplasmic
reticulum (ER) stress-induced proapoptotic factor CCAAT-element-binding protein homologous
protein (CHOP) as an important mechanism underlying HIV PI-induced inflammation and
hepatic lipotoxicity. However, little is known about the mechanistic pathways by which alcohol
promotes HIV PI-induced hepatic lipotoxicity. The aim of this study was to determine if
inhibition of CHOP expression prevents alcohol- and HIV PI-induced apoptosis and
dysregulation of lipid metabolism. We demonstrated that co-administration of alcohol and HIV
PIs induced unfolded protein response (UPR) activation, ER stress, and CHOP upregulation in
rodent hepatocytes. Both alcohol and HIV PI-induced lipid accumulation and apoptosis were
significantly reduced in CHOP-/- hepatocytes. Also, CHOP-/- hepatocytes treated with alcohol and
xiv

HIV PIs showed inflammation.. Activation of the ER stress-induced proapoptotic factor CHOP
is a key cellular mechanism underlying alcohol and HIV PI-induced hepatotoxicity. CHOP
expression is key for alcohol and HIV PI-induced dysregulation of key genes involved in lipid
metabolism in hepatocytes. Limitations of the study include the usage of global CHOP-/- in lieu
of tissue-specific conditional knockout mouse models, nonobservance of the effects of alcohol
and HIV PIs on extra-hepatic tissues, and incomplete investigation of the interplay of
hepatocytes and resident macrophages.

xv

INTRODUCTION
I. Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome
A.

Human Immunodeficiency Virus
According to the United Nations Program on HIV/AIDS, there were an estimated 36.9

million people globally living with HIV as of the end of 2016 1. The CDC 2016 United States
statistics estimates total new HIV infections at 39,782 2. While the rate of new HIV annual
infections and deaths has declined substantially with the introduction of impactful drug regimens,
HIV/AIDS remains among the leading causes of death within the United States. An estimated 1.2
million people are living with HIV/AIDS (PLWHA) in the United States, with the highest
prevalence rates observed being among men and members of ethnic minority groups. Although
the United States has experienced a regression of AIDS-related mortality, the financial burden of
HIV has become a concern as there are increased numbers of PLWHA that are enjoying longer
lifespans requiring lifetime treatment. Lifetime treatment of HIV/AIDS must account for costs
associated with medical care, HIV medications, and costs for treating co-morbid conditions 3.
Addressing the HIV epidemic demands accurate projections by researchers and careful
consideration of the necessary financial requirements by economic advisors and policy-makers to
evaluate resource allocation. In the early years of the HIV epidemic, the federal funding was a
small fraction of today’s budget, which has grown to more than $32 billion in the fiscal year 2019.
While resources are distributed for domestic intervention, research, and assistance programs, the
overwhelming majority of the U.S. federal funding for HIV/AIDS is assigned to domestic are and
treatment at approximately $21 billion 4.

1

Figure 1. The US. Federal Funding for HIV/AIDS. Allocation of federal funding for
HIV/AIDS by category from the fiscal year 2019. Foundation, H. J. K. F. (2019) U.S. Federal
Funding for HIV/AIDS: Trends Over Time, March 2019 Fact Sheet.
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HIV is found in body fluids, including semen, breast milk, blood, and vaginal fluid. HIV
transmission may occur during unprotected sex, contact with HIV-infected blood, sharing of
intravenous drug needles of HIV positive individuals, from HIV positive mother to child, and
during breast-feeding. HIV belongs to a family of lentiviruses, amongst a higher group of
retroviruses, and is associated with diseases of immunosuppression characterized by having
prolonged latency periods following infection and symptom presentations. HIV structure includes
a sphere-shaped lipid bilayer envelope with two viral RNA molecules and enzymes necessary for
replication and maturation. As retroviruses are unable to replicate outside of living host cells, HIV
generates copies of itself by invading new host cells and using the cell’s machinery to produce
viral DNA.
B.

Overview of HIV Life-Cycle
The life cycle of HIV begins with attachment to the cell-surface receptor CD4 of T cells,

by association with the viral envelope glycoproteins gp120 and gp41. Chemokine receptors CCR5
and CXCR4 serve as an avenue for HIV to facilitate entry into the cell. The fusion of the virus
and the CD4+ cell membrane activates host cell surface proteins allowing transport of the viral
RNA to the host cell nucleus. The HIV genome is RNA encoded while the human genome is
DNA, thus requiring HIV RNA to be converted to DNA before it can be incorporated into CD4+
T cells and multiply.

The viral RNA is converted to double-stranded DNA by reverse

transcription. Reverse transcription is accomplished through a virally encoded enzyme, reverse
transcriptase, to produce a single strand of DNA from the viral RNA. The viral genome is
incorporated into the cellular DNA inside the CD4+ cell nucleus by another viral enzyme called
integrase in a process known as integration. The viral DNA is used as a template by the host cell’s
RNA polymerase II to produce new viral RNA, which can be translated into viral proteins. At this
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point in the cycle, CD4+ T cells have effectively been transformed into factories for the production
of new HIV particles. To accomplish viral protein production, a third virally encoded enzymeHIV protease- is required to cleave viral polyprotein precursor into individual mature proteins 5.
New virions are created from the viral proteins at the cell surface, which then buds off with a
mature virus being released which can go on to infect new cells. In addition to CD4-lymphocytes,
HIV also can infect macrophages.
C.

HIV Pathogenesis
The immune system is responsible for protection against environmental agents that are

foreign to the body, including microorganisms and their byproducts, drugs, foods, chemicals, etc.
The immune system works to protect the body against foreign invaders, such as viruses, bacteria,
and parasites, by activating both innate and acquired immunity. Innate immunity is the first
response to any foreign substance in the body. Innate immunity is a rapid response taking place
within minutes to hours and is antigen nonspecific. Components of the innate immune systems
include natural barriers (skin, mucous membranes), serum proteins (complement), pattern
recognition molecules, and phagocytes and natural killer cells. Phagocytic cells are located
throughout the body and include granulocytes (basophils, eosinophils, neutrophils),
monocytes/macrophages, and dendritic cells. Phagocytes destroy pathogens by engulfing and
digestion as well as antigen presentation to cells of the acquired immune system.

Acquired

immunity is characterized by a slower immune response (days), specificity, memory, adaptiveness,
and discrimination between self and nonself. Specificity describes the ability of the cells of the
acquired immune system to recognize markers on pathogens and only respond to particular
molecular patterns. Another unique characteristic of acquired immunity is the property of
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memory, which is the ability to recall an interaction with pathogens and, with specificity, mounts
a faster and powerful response with a second interaction.
The acquired immune response also shows adaptiveness, a degree of flexibility, allowing
response to previously unseen molecules. The acquired immune response can be categorized by
host defense mechanisms into B-cell mediated response or humoral immunity and T-cell mediated
responses or cell-mediated immunity. B cells are activated upon recognition and binding of
specific antigen and in response, produce antigen-specific antibodies to neutralize the antigen by
optimizing phagocytosis or complement mechanisms inducing an inflammatory response.
Immunoglobulins are structurally conserved, consisting of two identical light chains and two
identical heavy chains connected by disulfide bridges. The five major classes (IgG, IgM, IgA,
IgE, and IgD) of immunoglobulins result from differences in the antigen-binding H chains
allowing unique biological function after recognition and binding of an antigen. In contrast to
mounting an immune response lead by B cell soluble antibody production and circulation to bind
specific antigens, T-cells circulate directly to the site of the antigen being displayed by antigenpresenting cells (APCs) through potent cell migration molecules termed chemokines. Recognition
of foreign antigens by pathogen-specific T cell receptors allows cognate interaction of APCs and
T cells to eliminate the foreign antigen. There are several types of T cells with varying functions
differentiated by cell surface markers, including CD4+ helper T cells (TH), CD8+ cytotoxic T cells
(TC), and CD25+CD4+ T-regulatory cells (Treg). TH cells function by secreting cytokines that
activate and enhance B cell antibody production, natural killer cells, and monocyte/macrophages.
TC cells respond to peptides restricted to MHC-I and engage in the contact-depending killing of
virally infected cells by release of perforin and granzymes triggering cell death. Treg cells show
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suppressive activity on the response of other lymphocytes, including CD4+ and CD8+ T cells, B
cells, dendritic cells, and NK cells.
As the cellular viral targets of HIV infection are the CD4 molecules of T cells, the
pathogenesis of HIV is distinguished by the viral-mediated progressive depletion of CD4+ T cells,
ultimately leading to an immunocompromised state susceptible to opportunistic infections. With
a larger population of individuals living with HIV, clinicians are faced with an increasing spectrum
of clinical manifestations 6. Initially, infected individuals experience flu-like symptoms, including
fever, sore throat, fatigue, myalgia, and lymphadenopathy 7. These symptoms prompt persons to
visit with health professionals where their condition is often diagnosed as experiencing nonspecific
viral infections. Upon establishment of the viremia set point and depletion of CD4+ T cells,
opportunistic infections (OIs) as a result of primary HIV infection are the most common presenting
clinical manifestations. OIs share an indirect correlation with the CD4+ T-cell count with HIVinfected patients becoming particularly susceptible when <200 CD4 T cells/mm3, which is often
the case in previously undiagnosed patients or patients that have not begun an antiretroviral drug
regimen.
Advanced HIV infection leads patients to experience pneumocystis, esophageal candidiasis
resulting in chest pain, and cytomegalovirus retinitis presenting with progressive vision loss 6.
With <100 CD4 T cells/mm3, HIV-infected patients suffer from disseminated mycobacterium,
toxoplasmosis with toxic encephalitis as the most common presentation, and cryptococcus
presenting in the central nervous system 6. Further depletion of CD4+ lymphocytes <50 T
cells/mm3 shows the presentation of tumors on the skin or mucosal surfaces associated with Kaposi
sarcoma. HIV-infection also results in metabolic and cardiac clinical manifestations with body fat
redistribution, hyperlipidemia, and increased cardiac disease

6

8, 9

. With the development of anti-

HIV therapeutics, there was a dramatic decline in the incidence of OIs in HIV-infected patients,
while cardiac and metabolic concerns have been elevated and propose significant clinical
implications.
II.

Anti-HIV Therapeutics

A.

Classes of HIV drugs
Global access to antiretroviral therapy has been the primary contributor to a steep decline

in deaths from AIDS-related causes. As researchers have come to understand more about the lifecycle of HIV and viral replication in the host cell, several pharmacological agents have been
introduced with each targeting different stages in HIV development. Currently, there are five
antiretroviral classes that are licensed for treatment of patients infected with HIV including
nucleoside/nucleotide reverse transcriptase inhibitors (NRTI), nonnucleoside reverse transcriptase
inhibitors (NNRTI), protease inhibitors (PIs), fusion and CCR5 inhibitors (FI and CCR5-I), and
integrase inhibitors (INI) 10.
NRTIs inhibit activity of HIV reverse transcriptase (RT) required for HIV replication as
analogs of endogenous 2’-deoxy-nucleosides and nucleotides and compete with endogenous
deoxynucleotides for incorporation. In their parent-forms, NRTIs are inactive, and activation
requires a series of phosphorylation steps by host cell kinases to form deoxynucleoside
triphosphates that are capable of viral inhibition

11

. Upon activation using host cell enzymatic

processes, incorporation of NRTIs act as chain terminators of viral DNA as they lack 3’-hydroxyl.
This drug group targets an early step in the HIV replication cycle, suppressing proviral DNA
synthesis prior to integration into the host cell genome 11.

7

While NRTIs are classified as competitive substrate inhibitors, NNRTIs bind
noncompetitively to the HIV-1 reverse transcriptase enzyme. NNRTIs inhibit the catalytic activity

2007
1987

1995

2003

Figure 2. Anti-HIV drug development history and diagram of the targeting of HIV at
different stages of the life-cycle. Current FDA-approved anti-HIV drugs target the HIV
lifecycle at different stages, including fusion/entry of host cell, reverse transcription, integration
of viral RNA, and virion production.
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of HIV-1 RT by binding to the allosteric binding pocket near the RT polymerase active site of the
p66 subunit resulting in a conformational change in the 3-D structure forming the NNRTIs binding
pocket (NNIBP)

12

. Although NNRTIs have shown to be successful in both the treatment and

prevention of HIV-1, drug resistance has proven to be an issue as point mutations in the NNIBP
hinders NNRTI binding 12. Continued development of NNRTIs has centered on improving activity
against mutations by screening various NNRTIs molecular structures as well as refining
pharmacokinetics.
Entry inhibitors, also known as fusion inhibitors, become important when addressing drug
resistance as they have been shown to be effective for the treatment of HIV-1 infection in
treatment-experienced patients who have evidence of HIV-1 replication despite ongoing
antiretroviral therapy. Entry inhibitors classified into three categories based on the nature of
inhibition: 1.) Attachment inhibitors- interfere with the attachment of the gp120 to CD4 receptors;
2.) coreceptor inhibitors- inhibit the interaction of the gp120-CD4 complex with the coreceptor,
CCR5, or CXCR4; 3.) fusion inhibitors- inhibit the fusion of viral and plasma membranes

13

.

Current FDA approved entry inhibitors are limited to a single CCR5 antagonist and a fusion
inhibitor while there are several other agents at various stages of development, including advanced
stages of clinical trials.
It was initially suggested that HIV-integrase would be a difficult drug target as numerous
copies of the enzyme enter the cell with the infecting virus. Later, this assumption was dispelled,
as it was shown that integrase inhibitors demonstrate a higher affinity for integrase in the presence
of viral DNA than purified integrase enzyme alone 14. Targeting the viral enzyme integrase by
integrase inhibitors interrupts the replication cycle of HIV-1 and inhibiting the integration of

9

proviral HIV-1 DNA into the host chromosomal DNA 15. This activity effectively blocks the newly
infected cell from producing viral progeny.
The Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
Adolescents outlined by the Department of Health and Human Services details criteria for
recommended combination antiretroviral regimens.

Initial combination regimens for the

antiretroviral-naïve patient include either an NNRTI-based (1 NNRTI + 2 NRTIs) or PI-based (1
or 2 PIs + 2NRTIs) regimens 16. NNRTI-based regimens are generally the initial therapy with the
strategy of moving to PI-based regimens later reducing patient exposure to PI-associated toxicity
16

B.

History of the Development of Highly-Active Antiretroviral Therapy
The history of the development of highly- active antiretroviral therapy (HAART) began

with rapid development efforts following the discovery of HIV. The awareness of HIV in the
United States commenced in 1981 with the seminal report of Pneumocystiscarinii pneumonia,
suggesting the possibility of a cellular-immune dysfunction that predisposes individuals to
opportunistic infections originating from a common exposure. Very soon after that, HIV was
isolated and sequenced with analysis revealing HIV-1 and HIV-2 status as immunodeficiency
associated lentiviruses belonging to a larger group retrovirus.

In 1982, the acquired

immunodeficiency syndrome was described as the occurrence together of a characteristic group or
pattern of symptoms with HIV-1 as the causative agent of the epidemic. Over the next several
years, HIV/AIDS demonstrated a destructive path with new HIV-infection rates perpetuating the
damage and AIDS deaths rising at an alarming rate. In 1986, the first antiretroviral therapy to
prevent and treat HIV/AIDS, zidovudine, also known as azidothymidine (AZT), was introduced
as a part of a clinical trial. Throughout the following decade, AZT, a nucleoside analog reverse

10

Table I. Classifications of FDA-approved Anti-HIV drugs. FDA-approved anti-HIV drugs as
of 2014 are classified based on the location of drug action, and mechanistic drug activity.
FDA-Approved Anti-HIV Drugs (1987-2014)

Extracellular

Antiretroviral Drug

Drug Activity

Number Approved

Interferes with
binding, fusion,

Entry & Fusion Inhibitors

2

and entry of HIV
to the host cell
11 Nucleoside analog
reverse-transcriptase

Reverse Transcriptase Inhibitors

Inhibits reverse
transcription

inhibitors (NRTIs)
5 Non Nucleoside
analog reversetranscriptase

Intracellular

inhibitors (NNRTIs)
Inhibits
integration of
Integrase Inhibitors

viral DNA into

3

the DNA of host
cell
Blocks viral
Protease Inhibitors

protease virion
production

Pharmacokinetic Enhancers

7 peptidic PIs
2 non-peptidic PIs
1
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transcriptase inhibitor was paired with several newly developed nucleosides as a dual therapy
treatment to quell the damage inflicted by HIV. This strategy proved marginally effective.
However, long-term treatment with AZT was particularly toxic with gastrointestinal and
neurological adverse effects.
In 1996, the “decade of HAART” began with the 11th International Conference on AIDS.
Important insights from the conference were the demonstration of the propagation of HIV
infection by rapid virion production, validating the necessity for antiviral treatment, HIV viral
load as an indicator of the disease progression and CD4+ T cell decline rates, and the
establishment of a triple-drug therapy incorporating protease inhibitors 17. With the beginning of
the HAART era, the triple-drug therapy became the standard of care, which greatly reduced
AIDS, AIDS-related deaths, and hospitalization. Contributing to the expansion of anti-HIV
therapeutics, HIV clinical trials methodology was standardized with FDA acceptance of viral load
as a surrogate marker and expedited review of drug submissions 17. In 1999, NNRTIs were shown
to be a potent antiretroviral therapy and better tolerated than combination NRTIs 18. In 2002, to
address suboptimal pharmacokinetics, lopinavir boosted with ritonavir was established as the
preferred protease inhibitor-based regimen

19

. In 2003, the development of fusion/entry and

CCR5 inhibitors represented a unique class of antiretroviral medications answering the challenge
of drug resistance in treatment-experienced patients

13

. The “decade of HAART” was mostly

successful in fighting the HIV pandemic curtailing mortality rates and extending the lives of
patients while ushering in the modern HAART era.
Continued investment in HIV/AIDS research identified important drug targets,
groundbreaking clinical trials, and novel antiretroviral drug classes. In 2007, integrase inhibitors
were introduced (raltegravir) and demonstrated profound clinical efficacy in reducing HIV RNA

12

loads

15

. Significant advances in anti-HIV care also included guidelines and directives for

treatment.

It was proposed that lifetime control of HIV infection may be possible with

antiretroviral drugs by restricting the viral load under 50 copies/ml thus limiting the risk of new
resistance mutations

20

. Detrimental to the HIV maintenance, it was generally accepted to

discontinue therapy guided by CD4+ T cell numbers with attempts to boost immunity, address
toxicity concerns, and attenuate financial burden. In a large cohort study, it was shown that
episodic antiretroviral therapy guided by the CD4+ count significantly increased the risk of
opportunistic disease due to reduced CD4+ cell count and increased the viral load providing no
protection from adverse events associated with continuous antiretroviral therapy 21. Similarly, in
regards to treatment adherence, clinical studies highlighted the importance in that adherence to
protease inhibitor therapy required a threshold of 95% to optimize treatment and virologic
outcome for patients with HIV infection 22
C.

HIV Protease Inhibitors
Initially, the standard of care for HIV treatment centered on nucleoside reverse

transcriptase inhibitor monotherapy, such as azidothymidine (AZT) 23. In the mid-1990s, HIV-1
protease inhibitor drugs were administered in combination with reverse transcriptase inhibitors
beginning the first iteration of the HAART- a combination of multiple different classes of antiHIV drugs. The first generation PIs to market arrived in 1995 with saquinavir and with the
HAART treatment greatly improved patient outcomes by reducing viral loads, improving CD4 cell
counts, and halting the progression to AIDS

23

. Shortly following came to the development of

Ritonavir with a very potent Ki of 0.015 nM. However, it was later shown to be a potent inhibitor
of cytochrome 450/3A, a major metabolic enzyme for protease inhibitors 23. As a result, ritonavir
is primarily used as a pharmacokinetic booster than a protease inhibitor.. A second-generation PI,
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Lopinavir, was developed to improve upon the properties of ritonavir and is commonly
administered in combination with ritonavir, which serves as a pharmacokinetic booster. Today,
there are a total of eight FDA approved and licensed HIV PIs with different dosages and
combinations.
The incorporation of HIV PIs in HAART has successfully suppressed viral loads while
raising peripheral blood CD4 cell count in HIV patients, significantly reduced morbidity and
mortality, and changed HIV infection from an acute disease with high morbidity and mortality to
a manageable chronic disease. Early initiation upon HIV infection and adherence to antiretroviral
treatment are critical to treatment success. Unfortunately, HAART treatment, particularly PIs, is
associated with serious side effects with hepatic and metabolic toxicities.
D.

HIV Protease Inhibitor-induced Toxicity
Since their introduction in the mid-1990s, while HIV PIs have shown to be integral

components of the standard treatment of HIV infection, the use of HIV PI-based HAART has been
associated with hepatotoxicity, lipodystrophy, and occurrence of metabolic and cardiovascular
abnormalities including insulin resistance and atherosclerosis 24. Hepatotoxic effects have been
associated with HIV PIs at rates up to ~10% in randomized controlled trials and are compounded
by underlying liver diseases.
Despite the clinical success of HIV PI-based HAART regimens, there has been a temporal
occurrence with the prevalent development of lipodystrophy. Lipodystrophy is a condition of fat
redistribution and accumulation with loss of peripheral subcutaneous adipose tissue (lipoatrophy)
mostly in the limbs, face, and buttocks, and accumulation of adipose tissue in the intra-abdominal
space, the dorso-cervical regions (buffalo hump) and the breasts 25. Lipoatrophy is influenced by
the balance of the rate of differentiation of adipocytes, size, and rate of cell death. Interestingly,
14

Table II. FDA-approved HIV protease inhibitors for the treatment of HIV/AIDS. FDAapproved HIV protease inhibitors with corresponding brand names and commonly adopted
abbreviations.
HIV PI

Brand Name
FDA Approval Date
1 Generation of HIV PIs
Peptidomimetic inhibitors
Structural analogs of the HIV Phe-Pro protease cleavage site
Amprenavir
Agenerase
APV, 4/14/1999
Atazanavir
Reyataz
ATV, 6/20/2003
Indinavir
Crixivan
IDV, 3/13/1996
Lopinavir
Kaletra, Aluvia
LOPV, 9/15/2000
Nelfinavir
Viracept
NFV, 3/14/1997
Ritonavir
Norvir
RTV, 3/1/1996
Saquinavir
Fortovase
SQV, 12/6/1995
nd
2 Generation of HIV PIs
Nonpeptidic Protease Inhibitor
Darunavir
Prezista
DRV, 6/23/2006
Tipranavir
Aptivus
TRV, 6/22/2005
st
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HIV PIs have been linked to the promotion of lipoatrophy by disturbing adipocyte viability and
preventing the replacement of apoptotic adipocytes by inhibiting pre-adipocyte differentiation 26.
Ritonavir exposure has been identified as resulting in decreased expression of markers associated
with adipocyte differentiation, and the impact is compounded when administered with NRTIs 27.
As of June 2015, UNAIDS approximates 15.8 million people living with HIV were
accessing antiretroviral therapy. As a result, there is a concern with increased clinical incidents of
HIV PI-induced toxicity. Many risk factors of HAART-based liver injury contribute to the
exacerbation of the damage incurred in individual patients, including concurrent abuse or use of
alcohol

28

. Studies have shown in patients with acute/early HIV infection, a large proportion

reported a pre-HIV history of alcohol abuse disorder and found it increasingly challenging
managing HIV with the pre-existing alcohol abuse and depression 29
III.

Alcoholic Liver Disease
The National Survey on Drug Use and Health (HSDUH) conducted in 2015 reports 15.1

million adults ages 18 and older had Alcohol Use Disorder. The CDC estimates 88,000 people in
the US die from alcohol-related causes annually, making alcohol the third leading preventable
cause of death behind tobacco, poor diet, and physical inactivity. The national economic burden
associated with excessive alcohol consumption in 2010 was listed at $249 billion with large total
costs appropriated to health care services with no clear intervention strategies being initiated to
reduce the burgeoning financial encumbrance passed on to taxpayers

30

. The development of

alcoholic liver disease (ALD) serves as the major cause of morbidity and mortality associated with
alcoholism and significant drain of healthcare resources as treatment is currently limited to liver
transplantation for end-stage disease 31.
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A.

The spectrum of Alcoholic Liver Disease
The spectrum of ALD ranges from simple steatosis, acute alcoholic hepatitis, fibrosis, and

cirrhosis with an overlap of clinical and pathological manifestations. Steatosis is a fatty liver
condition that is the earliest and most common response of the liver to chronic or acute alcohol
consumption. The prevalence of steatosis ranges from 90-95% of alcohol consumers, with the
primary treatment being abstinence from ethanol with pharmacological therapy used in severe
cases. Generally, steatosis is asymptomatic with normal or mildly elevated liver enzymes levels.
Histologically, fatty liver is characterized by large lipid droplets in the cytoplasm of hepatocytes
without significant inflammation or necrosis

32

. What was once considered to be a benign

condition, steatosis, has recently been identified as a significant risk factor for advanced forms of
ALD as the accumulation of lipid results in an inflammatory response. If drinking continues,
alcohol-induced steatosis leaves individuals susceptible to severe pathology, including alcoholic
steatohepatitis 33, fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC).
ASH is estimated to occur in 10% to 35% of heavy drinkers and is associated with poor
prognosis 32. ASH results in parenchymal cytokine/chemokine production initiating subsequent
infiltration of inflammatory cells and hepatocellular damage, significantly elevating the risk of
developing to fibrosis and cirrhosis.

Individuals with ASH may present with the mild

asymptomatic disease to severe disease linked to elevated liver enzyme levels, hepatomegaly,
jaundice, and fever. Histological features of ASH include ballooning of hepatocytes, neutrophilic
infiltration, Mallory hyaline, and fibrosis that resembles “chicken-wire” in appearance. ASH
development to progressive fibrosis is indicated by excessive accumulation of collagen bands and
other extracellular matrix proteins produced by hepatic stellate cells in response to cytokine
activation. Persistent ASH advances to cirrhosis defined by the occurrence of extensive fibrosis

17

and hepatocellular nodule formation 34. Cirrhosis remains among the leading causes of death in
the United States and is the most common predisposing factor for HCC. Cirrhosis-associated
regenerative nodules may progress along a carcinogenic pathway to become HCC composed of
malignant neoplasms derived from the dedifferentiated hepatocytes 35.
The most impactful non-genetic or environmental ALD risk factor is the continued
heavy alcohol consumption as there is a clear dose-dependent relationship between the amount of
alcohol and ALD incidence. Additionally, an essential promoter of ALD progression is viral
hepatitis co-infection (hepatitis B, hepatitis C). A similar association in fibrosis progression has
been established between alcohol use, viral hepatitis, and HIV coinfection. Additionally, obesity
and insulin resistance are known causes of the steatohepatitis and may exacerbate the effects of
alcohol on fibrosis. Increasingly, the host genetic factors to the risk of ALD are being recognized.
Although men consume more alcohol than women and, as a result, dominate the incidences of
ALD, women are more exposed to hepatotoxic effects likely attributable to differences in alcoholmetabolizing enzymes. Another consideration is nucleotide polymorphisms in ALD relevant
genes. Genome-wide association studies identified patatinlike phospholipase-domain containing
protein 3 (PNPLA3) is important for the evolution of steatosis, inflammation, fibrosis, and HCC
34

.

B.

Pathogenesis of ALD
Global epidemiological studies have illustrated the devastating effects of chronic and

excessive alcohol consumption and resultant liver injury. As alcohol is primarily metabolized in
the liver, a large proportion of alcohol abusers suffer from ALD. The liver hepatocytes are chiefly
affected by alcohol consumption as this cell type expresses the highest levels of ethanol-oxidizing
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Figure 3. The spectrum of alcoholic liver disease (ALD). The spectrum of ALD begins with
simple steatosis with an eventual progression to steatohepatitis and fibrosis. Alcoholic
steatohepatitis with continued alcohol abuse may advance to liver cirrhosis and a small
population to hepatocellular carcinoma. Genetic and environmental factors have been identified
in modulating ALD. European Association for the Study of the Liver. EASL clinical practical
guidelines: management of alcoholic liver disease. J Hepatol 2012;57:405
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enzymes, including alcohol dehydrogenase (ADH), cytochrome P450 2E1 (CYP2E1), and catalase
36

. There are three pathways in liver hepatocytes that result in the oxidation of ethanol to

acetaldehyde through enzymatic activity 37. The major pathway for the oxidation of ethanol to
acetaldehyde occurs in the cytosol, where ADH with a reduction of the cofactor nicotinamide
adenine dinucleotide (NAD+). The major inducible pathway is mediated by the action of CYP2E1
in the ER, where its metabolic ratio can increase up to 3-fold in hepatocytes and Kupffer cells
when alcohol is consumed 38. Moreover, chronic alcoholics develop a tolerance to alcohol due to
elevated CYP2E1 activity 39. A consequence of increased CYP2E1 activity and the conversion of
ethanol to acetaldehyde in the presence of molecular oxygen is the production of toxic metabolites
and resulting hepatocellular injury. The hepatic accessory pathway occurs in the peroxisome with
the oxidation of alcohol to acetaldehyde via hydrogen peroxide conversion to water by catalase.
An approach to minimize toxicity associated with the generation of highly reactive acetaldehyde
is the rapid mitochondrial oxidation to acetate by aldehyde dehydrogenase 2 (ALDH2) 37. As a
byproduct of ALDH2 oxidation of acetaldehyde to acetate, there are significant changes in cellular
redox potential shifting from oxidative metabolism to reductive synthesis promoting lipid
synthesis by increased expression of lipogenic enzymes and development of fatty liver condition
40

.
Another concern contributing to alcohol-induced liver injury and hepatic steatosis is

dysregulation of lipid homeostasis in adipose tissue. Dietary fats in excess of requirements are
digested and converted into triacylglycerols that eventually arrive in the adipose tissue and stored
as fatty acids serving as an energy stockpile. Numerous studies have detailed the insulin feeding
41, 42

. Moreover, adipose tissue-derived free fatty acids following alcohol exposure accumulate in
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Figure 4. Hepatocyte ethanol metabolism pathway.

Ethanol is mainly metabolized to

acetaldehyde in the cytosol of hepatocytes through alcohol dehydrogenase in the major inducible
pathway. The ER participates in ethanol metabolism through the actions of the CYP2E1 enzyme.
Peroxisomal ethanol metabolism by way of catalase-mediated oxidation presents an accessory
pathway. Mitochondrial oxidation of acetaldehyde by aldehyde dehydrogenase converts ethanol
to acetate that is released into circulation. Osna, N. A., Donohue, T. M., Jr, & Kharbanda, K. K.
(2017). Alcoholic Liver Disease: Pathogenesis and Current Management. Alcohol research:
current reviews, 38(2), 147–161. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513682/
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the liver and are converted back to triglycerides 43.
While alcohol is the culprit behind hepatic lipotoxicity, clinical studies have shown that
alcohol alone is necessary but not sufficient to induce liver injury. Alcohol exposure-induced gut
permeability and leakage of gut endotoxins, namely lipopolysaccharide (LPS), presents another
challenge advancing liver inflammation and injury. Upon chronic alcohol exposure, LPS enters
the portal vein with circulation to the liver contributing to alcoholic hepatitis through activation
and polarization of liver KCs to the M1 pro-inflammatory phenotype. KC activation is initiated
by the interaction of LPS with Toll-like receptor 4 (TLR4) yielding production of chemokines and
proinflammatory cytokines resulting in hepatic injury

44

. Kupffer cell-induced tumor necrosis

factor-α (TNFα) production is responsible for initiating cell death mechanisms and chemokinemediated recruitment of proinflammatory lymphocytes, including neutrophils, T-cells, hepatic
stellate cells, and circulating macrophages 37. Studies have shown the hepatocellular damage and
liver steatosis is significantly reduced in TNFα-/- mice when compared to wild-type littermates 45.
C.

HAART and Alcohol
The development of HAART in the care of HIV-positive individuals has led to tremendous

improvement in patient outcomes. The disease has transformed from invariably lethal into
manageable chronic ailment with a life expectancy of nearly approaching that of the HIV-negative
population 46. To facilitate this prognosis, strict adherence to PIs is necessary for optimal HIVRNA suppression. With a new HIV-infection and subsequent initiation of HAART treatment,
consideration must be made for an individual’s lifestyle characteristics. Reasons suggested by
patients for not fully adhering to HAART vary from simple forgetfulness to being busy and/or
away from home47. Other reasons for loose adherence to HAART are more problematic involving
alcohol and substance abuse. Alcohol consumption is common among people in care for HIV,
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with rates of moderate to heavy drinking almost twice those found in the general population, and
is associated with worse HAART compliance, which can affect disease progression

29

. As the

majority of deaths after the establishment of HAART are no longer AIDS-associated, but rather
an end-stage liver disease, alcohol along with HAART has been identified as bilateral causes of
mortality due to metabolic complications and hepatotoxicity.
D.

ER stress and ALD
With alcohol metabolized in the body primarily by ADHs in the liver, where parenchymal

cells contain an abundance of ER, attention has been directed towards the association of alcoholinduced ER stress and the underlying molecular mechanisms. With both chronic and acute
exposure, alcohol and its metabolites produce an array of injuries, including inflammation,
apoptosis, fibrosis, and steatosis. In vivo models by intragastric alcohol delivery in rodents have
revealed elevated ER stress markers accompanied by liver steatosis and apoptosis chiefly caused
by oxidative stress, acetaldehyde accumulation, and disruption of intracellular calcium
homeostasis 48. Moreover, C/EBP homologous protein (CHOP) has been specifically identified in
alcohol-induced apoptosis and hepatocellular damage with CHOP-/- mice showing protection 49.
However, as illustrated with CYP2E1 selective inhibition where liver triglycerides were
significantly decreased yet ER stress markers remained elevated, the ER stress response and
subsequent hepatic injury after alcohol exposure are activated not just solely from ethanol
metabolism-induced oxidative stress

50

. HIV PIs have also been shown to disrupt intracellular

calcium homeostasis and may potentiate ALD-induced ER stress and injury 51
IV.

ER Stress and the Unfolded Protein Response (UPR)
The hepatocytes are the chief functional cells of the liver and are ER-rich in composition.

The ER serves as the cellular site of protein synthesis and transport, protein folding, lipid, and
23

steroid synthesis, carbohydrate metabolism, and calcium storage 52. Hepatocyte lipid biogenesis
is important for maintaining the structural integrity of biological membranes forming hydrophobic
barriers that allow compartmentalization of functions and protection from the environment.
Additionally, lipid membranes are used for energy production. Phospholipids are transferred and
biochemically modified at the ER-Golgi intermediate compartment (ERGIC) and distributed
throughout the cell via organelle contacts or secretory vesicles

52

. Calcium regulation and

homeostasis is also an important utility of the ER as it serves as an intracellular reservoir. Calcium
is a signaling molecule that affects many processes, including localization and function of proteins
as well as signal transduction pathways.

The functionality of calcium dictates that its

concentration, both extracellularly and intracellularly, be maintained within a very narrow range.
The typical cytosolic Ca2+ concentration (50-100 nM) is approximately 1/1000th of the
extracellular Ca2+ concentration. When intracellular Ca2+ levels are low, the ER contains several
calcium channels that allow Ca2+ release from the ER into the cytosol. Conversely, the event of
depletion of ER Ca2+ stores instigates an influx of extracellular Ca2+ via plasma membrane Ca2+
channels in a mechanism known as store-operated Ca2+ entry (SOCE).
Intracellular calcium homeostasis under the advisement of the ER can also affect the
function and association of proteins. The rough ER has a cytosolic surface studded with ribosomes
that manufacture all secreted proteins, as well as, integral membrane and cytosolic proteins.
Synthesis of secreted or plasma membrane proteins initiates when messenger RNA binds to a free
ribosome in the cytosol and is then recruited to the ER membrane by the interaction between the
signal sequence of the polypeptide and the signal recognition particle (SRP). After binding the
signal sequence, the SRP docked the actively synthesizing ribosome to the SRP receptor and
transitioned to the translocon, which forms a channel into the interior of the ER. Following SRP
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disassociation from the mRNA-ribosome-polypeptide complex, translation continues, and the
polypeptide enters the ER lumen or is incorporated into the ER membrane. Integral membrane
proteins are characterized by an internal signal sequence, rather than an N-terminal sequence,
stopping the translocation of the protein and anchoring within the phospholipid bilayer. These
proteins may have both an N-terminal signal sequence and an internal stop-transfer sequence, or
an internal signal sequence and an internal stop-transfer sequence resulting in multiple pass
membrane proteins. For secreted proteins, upon translation termination, the ribosome is released,
and the translocon channel reverts to a narrow confirmation. The newly synthesized protein then
must assume the correct folding pattern in order to function properly and avoid incorrect formation
or aggregation with other polypeptides. Chaperone proteins and folding enzymes prevent protein
misfolding by chemical modifications (N-linked glycosylation, disulfide bridges) and
oligomerization.

The protein is then packaged and sent to the Golgi apparatus for further

modifications and packaging within different vesicles for secretion. As a part of the cell’s quality
control mechanism, misfolded or aggregated proteins are transported to the cytosol and destroyed
by the proteasome through the ER-associated degradation pathway.
Maintenance of cellular homeostasis includes the processing of newly synthesized
proteins, which enter the ER lumen in an unfolded state and undergo folding and post-translational
modifications. A significant amount of incoming proteins are degraded in response to improper
folding. ER stress occurs as the accumulation of unfolded proteins exceeds the processing capacity
of the ER. Additionally, the cell experiences ER stress with glucose deprivation or changes in
intracellular calcium levels 53. In an attempt to reestablish ER homeostasis and alleviate ER stress,
an evolutionarily conserved pathway termed the UPR is triggered
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54

. If the UPR is unable to

manage the ER unfolded protein load, the cell responds by activating a pathological response of
lipogenesis, inflammation, and under chronic ER stress-activation of apoptosis and cell death 55.
The UPR functions by cytoprotective and compensatory mechanisms, including ER protein
chaperone-assisted protein folding and the ER-associated degradation pathway (ERAD), which
mitigated the increase in degradation of misfolded proteins 56. The UPR consists of three main
transmembrane protein ER stress sensors, including inositol-requiring enzyme 1 (IRE1), protein
kinase ds-RNA-dependent-like ER kinase (PERK), and activating transcription factor-6 (ATF6).
The 78-kD glucose-regulated/binding immunoglobulin protein (GRP78) is an ER chaperone that
binds to transmembrane sensors causing them to remain in an inactive state 55. Upon stress, GPR78
dissociates from the stress sensor to enhance protein-folding activity. The IRE1 pathway is the
most highly conserved ER stress sensor and is able to detect unfolded proteins in the ER lumen
resulting in the activation by receptor oligomerization and autophosphorylation of the cytosolic
domain

57

. IRE1α is an endoribonuclease that processes the mRNA encoding unspliced X-box-

binding protein 1, resulting in an active transcription factor for genes involved in ER protein
synthesis and folding, ERAD, autophagy, and lipid biogenesis (Hetz, 2012, Bravo, 2013). The
PERK pathway represents another of the transmembrane protein ER stress sensors and acts to
inhibit protein synthesis by phosphorylation of eukaryotic translation initiation factor-2α (eIF2α).
Moreover, phosphorylation of eIF2α selectively increases the translation of activating transcription
factor 4 (ATF4). Among the regulation of genes related to protein folding and autophagy, ATF4
translation yields the activation of CHOP, an ER-stress-induced proapoptotic factor (Hetz, 2012,
Bravo, 2013). The ER stress sensor ATF6 pathway is characterized by the encoding of the basic
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Figure 5. Unfolded protein response. The three transmembrane transducers PERK, ATF6, and
IRE1 are activated upon dissociation with the master regulator Bip/GRP78.

PERK

phosphorylates the eIF2α halting protein translation and activating ATF4. ATF6 is translocated
to the Golgi and proteolytically processed sequentially by site-1 protease and site-2 protease
yielding active ATF6N, which controls the expression of key genes involved in ERAD and XBP1. IRE1 upon activation splices XBP-1 to its active form where it is able to enter the nucleus and
regulate the ER stress response element that induces transcription of genes that involved in the
regulation of lipid metabolism and ER membrane expansion. Chronic ER stress results in the
induction of cellular apoptosis pathways mediated by CHOP transcription.
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Leu zipper (bZIP) transcription factors 58. When the cell experiences ER stress, ATF6 translocates
to the Golgi apparatus, where it is cleaved into fragments (ATFα,β,f), which then translocate to
the nucleus and promote transcription of ERAD genes and XBP1 58. Together, the three branches
of the UPR contribute to reestablishing ER homeostasis in stressed cells. When the cell cannot
keep pace with the accumulation of unfolded proteins there is a pathological response of
lipogenesis, inflammation, and activation of the apoptotic pathway 55.

A.

ER stress and Autophagy
Autophagy is a catabolic process that eliminates and recycles cytoplasmic materials such

as misfolded proteins, damaged organelles, and invading pathogens by lysosomal degradation in
a protective role and support of cellular nutrient homeostasis 59. In mammalian cells, three discrete
subtypes of autophagy have been described with distinct physiological functions and transport
mechanisms

for

lysosomal

degradation

including

chaperone-mediated

autophagy,

macroautophagy, and microautophagy 60. Chaperone-mediated autophagy utilizes the chaperone
protein heat shock cognate 71 kDa protein to target substrates to the lysosome by binding to the
lysosome-associated membrane protein type 2A (LAMP-2A)

61

. Less is known regarding the

mechanism of microautophagy while it is understood the process involves internalization of
cytosolic constituents by invagination of the lysosomal membrane. Macroautophagy, hereafter
referred to as autophagy, is most studied and reviewed autophagic process and is characterized by
the formation of double-membraned vesicles termed autophagosomes in which cytosolic materials
are sequestered to later fuse with lysosomes for degradation. While cells maintain basal levels of
autophagy as a homeostatic mechanism of waste elimination, cellular nutrient starvation is a
known trigger for autophagy induction and the initiation of a recycling process with the
degradation of macromolecules to generate metabolic substrates for the biosynthesis of new
28

proteins

62

. Although the mechanism of action remains unclear, ER stress has been linked to

autophagy activation in both alleviating the UPR in protein degradation and as an alternative
pathway to cellular apoptosis termed autophagic cell death (or type II cell death)

62

. The dual

cytoprotective and cytotoxic processes of autophagy requires further investigation.
The molecular mechanisms of autophagy exist in a complex array of factors starting from
the initiation of autophagy through autophagosome formation and fusion with lysosomes for
proteolytic degradation. A multitude of autophagy-related genes (ATG) have been discovered to
function at different stages of the pathway. Upon nutrient deprivation or cellular stress, mTOR
(mechanistic target of rapamycin) inhibition results in a ULK1/2 (Uncoordinated-51 Like
Autophagy Activating Kinase 1 & 2) (mammalian homologs of ATG1), FIP200 (ortholog of yeast
ATG17), and ATG 13 complex formation responsible for autophagy initiation

60

. Phagophore

formation is achieved under the direction of the class III phosphatidylinositol 3-kinase (PtdIns3K)
complex composed of the (PtdIns3K) enzyme, its accompanying regulatory component with
accessory protein Beclin 1 (homolog of ATG6), and ATG14 63. The association of Beclin 1 with
the antiapoptotic protein Bcl-2 renders the inhibition of (PtdIns3K) and autophagy induction. The
expansion and closure of the phagophore involve several ubiquitin-like (UBL) protein conjugation
systems performing conjugation reactions of ATG5-ATG12 and phosphatidylethanolamine-LC3
(microtubule-associated protein 1A/1B-light chain 3)

60, 63

. The same E1 ubiquitin-activating

enzyme, ATG7, facilitates both conjugation reactions upon autophagy induction. The ATG5ATG12 conjugate is responsible for the lipidation of LC3 spawning membrane biogenesis and
autophagosome formation 59.
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B.

ER stress and Inflammation
The ER is tasked with the synthesis, processing, and transport of biomolecules, including

proteins, lipids, glycogen, and other steroidal compounds (cholesterol, sex hormones, etc.). With
disruptions in protein folding homeostasis or other cellular stressors, the UPR responds to restore
order and cellular viability. Studies have established an interconnection of the ER stress and
inflammatory pathways as inflammatory cytokines may trigger UPR activation and ER stress,
and ER stress may initiate inflammation to counteract tissue damage 64. Moreover, a prolonged
UPR can further amplify the ER stress-induced systemic inflammation through the increased
cleavage of the ER-localized inflammatory transcription factors. A role of chronic ER stress has
been recognized in several inflammatory chronic diseases, including atherosclerosis,
cardiovascular diseases, and many metabolic diseases 64.
The integration of ER stress, inflammatory, and metabolic responses are influenced by
various intrinsic factors but mainly by reactive oxygen species (ROS) production and changes in
intracellular calcium levels.

Calcium orchestrates intracellular signaling through protein

phosphorylation/dephosphorylation events to drive gene transcription and cell proliferation,
among other cellular processes. The concentration of calcium in the ER lumen is many orders of
magnitude greater than in the cytosol and is mobilized from the internal stores through second
messengers binding with the inositol 1,4,5-triphosphate receptor (Ins(1,4,5)P3R) and the ryanodine
receptor (RyR)

65

. ER calcium sink is maintained by active uptake across the ER membrane

through the Sarcoplasmic/ER calcium-ATPase (SERCA) and calcium-binding factors.

The

plasma membrane Ca2+-ATPase and the Na+/Ca2+ exchanger are responsible for the efflux of
calcium from the cell. The mitochondria assist in cellular calcium homeostasis through the
accumulation of cytosolic calcium via a uniporter into the mitochondrial matrix. The balancing
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act of the sequestering of intracellular calcium and calcium release from intracellular stores is
critical for cellular homeostasis and survival. In addition, calcium in the ER is necessary for early
protein processing under oxidative conditions allowing nascent polypeptide chains to form
disulfide bonds 64, 66. As this process is coupled to the phosphorylation of eIF2, depletion of ER
calcium levels results in a decrease in the inhibition of translation initiation

66

. More recently,

calcium has been implicated in having a role in the regulation of cell death mechanisms of
apoptosis and autophagy 67.
ER stress has been shown to cause a leak of calcium from the ER stores and induction of
mitochondrial calcium accumulation resulting in cellular apoptosis

68

. Increases in ER and

mitochondrial calcium contribute to the production of harmful reactive oxygen species (ROS)- a
mediator of inflammation and oxidative stress conditions. ROS are generated as a consequence
of normal metabolic functions where the oxygen molecule accepts an additional electron to create
the highly reactive and toxic form of oxygen superoxide 69. Protein folding in the ER requires
oxidative conditions and is estimated to be responsible for up to 25% of cellular ROS production
60

. Low levels of ROS play important roles in the cell as ROS are produced in the ER lumen as a

byproduct of disulfide bond formation by the oxidoreductase protein disulfide isomerase (PDI).
The oxidation of molecular oxygen by ERO-1 (ER oxoreductin 1) to provide oxidative power for
PDI in disulfide bond formation is responsible for the ER protein folding-induced ROS production
oxidative stress 64, 70. Increased protein folding responsibility leading to chronic UPR activation
and ER stress can generate ROS production and trigger an inflammatory response 71. Moreover,
calcium and ROS interrelate in a bidirectional cooperative amplification loop where excessive
calcium influx results in the activation of ROS generating enzymes and ensuing oxidative stress,
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while increased ROS generation targets ER-based calcium channels and stimulates elevated
calcium signaling 72, 73.
The crosstalk of ER stress and the inflammatory response is largely mediated through the
activation of NF-κB. NF-κB is a master transcriptional regulator in mediating pro-inflammatory
pathways in response to inflammatory stimuli, cellular stress, and apoptosis

64

. Under normal

physiological conditions, NF-κB is rendered inactive in the cytoplasm through binding with the
constitutively expressed family of inhibitors of NF-κB (IκB). NF-κB activation necessitates
signal-induced phosphorylation and subsequent degradation of IκB by IκB kinase (IKK) 74. IKK
has shown to be activated by diverse stimuli including cytokines TNFα, IL-1, stress agents, and
infections compounds detected by pattern-recognition receptors (PRR)- namely TLR4

75

.

Disassociated and activated NF-κB utilizes a nuclear-localization signal to facilitate translocation
to the nucleus, at which point NF-κB stimulates transcription of inflammatory genes.
All three arms of the UPR (PERK, IRE1α, ATF6) have been indicated as capable of NFκB activation.

IRE1α responds to ER stress by autophosphorylation and induction of

conformational change to bind with an adaptor protein TNFα- receptor-associated factor 2
(TRAF2) 74. The IRE1α-TRAF2 interaction allows the recruitment of IKK ultimately leading to
the degradation of IκB and NF-κB nuclear translocation. In a similar fashion, the IRE1α-TRAF2
complex activates the mitogen-activated protein kinase (MAPK) c-Jun N-terminal kinase (JNK)
pathway instigating expression of pro-inflammatory genes via the activation of the apoptosis
signal-regulating kinase 1 (ASK1) 76. The PERK division of the UPR promotes NF-κB activation
through the PERK-eIF2α-mediated attenuation of translation suspending protein synthesis causing
an imbalance of NF-κB/ IκB, as IκB a has a shorter half-life than NF-κB, yielding a lack of the
NF-κB inhibitory factor thus enabling NF-κB nuclear translocation and activation of its target
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genes

75, 76

. Upon Bip/GRP78 disassociation inducing the UPR, the ATF6 signaling pathway

functions by PI3k-Akt (Protein Kinase B) phosphorylation leading to NF-κB activation although
the mechanism requires further investigation 77. Additionally, cyclic adenosine monophosphate
(cAMP)-responsive element-binding protein H (CREBH), mainly expressed by hepatocytes and
activated by S1P and S2P cleavage, acts synergistically with ATF6 to activate acute-phase
response genes serum amyloid P (SAP) and C-reactive protein (CRP) inducing systemic
inflammation 78.
Inflammation is involved in several metabolic and chronic liver diseases and is mediated
by several factors in the ER as previously discussed. Another element contributing to the
inflammatory cascade and liver disease is the activity of the nucleotide-binding oligomerization
domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome in response to
ER stress. Inflammasomes are constituents of the innate immune response and are multiproteincomplexes expressed in primarily in myeloid cells (monocytes, tissue-resident macrophages,
dendritic cells) as well as non-immune cells in the liver (hepatocytes, stellate cells) and is
upregulated in response to pathogen-associated molecular patterns (PAMPs) and sterile insults 79.
NLRs are a subset of PPRs that function as intracellular sensors of stress and respond by mounting
an immune response. There are distinct classes of NLRs with classification being based on shared
three-domain structural homology of the pyrin domain (PD), a caspase-recruitment domain, or a
baculovirus inhibitory-repeat domain 80. A common feature of all NLRs is the central nucleotidebinding oligomerization domain (NATCH) and the leucine-rich repeats (LRR).
The NLRP3 is the most widely studied and characterized inflammasome and operates
through the PD recruitment of the adaptor protein ASC (an apoptosis-associated speck-like protein
containing a CARD domain). The ASC allows the recruitment of cysteine protease caspase-1,
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which undergoes autocatalysis, rending the active form that cleaves pro-IL-1β and pro-IL-18 to
their active secreted forms. The mechanisms of NLRP3 activation remains unclear. However, its
activation requires a priming step. In studies using obese mice experiencing hepatosteatosis, the
whole liver analysis revealed overexpression of CHOP and NLRP3 inflammasome activation
resulting in hepatocyte pyroptosis and apoptosis 81. NLRP3-induced liver injury and fibrosis have
been demonstrated in hepatocytes, stellate cells, and liver KCs 81-83. ER stress induced-ROS also
has been identified as a trigger of inflammasome formation and activation and functions as an
effector molecule in exacerbating inflammasome activity 84. Similarly, CHOP-mediated depletion
of the ER calcium store results in an amplification of NLRP3 inflammasome activation 85. These
studies have identified the role of the NLRP3 inflammasome in sensing and responding to ER
stress representing an alternative mechanistic link between ER stress and chronic inflammatory
diseases 86.
V.

Hepatic Lipid Metabolism

A.

Lipid Metabolism in the Liver
Lipids are biological molecules made up of hydrocarbons that play a critical role in cellular

membrane structure as well as metabolic and hormonal pathways. Fatty acids are straight-chain
carbon compounds with a terminal carboxyl group. Triglycerides are composed of three fatty acid
units esterified with glycerol. Phospholipids consist of two fatty acids linked to glycerol and a
phosphate group. Cholesterol found exclusively in animals, is made up of four hydrocarbon rings
linked together to form a steroid structure with a hydroxyl group at the other end. Cholesterol is
the precursor of steroid hormones and bile acids that are used in fat digestion in the gut. A large
proportion of plasma cholesterol is esterified with fatty acids to form cholesterol esters.
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Physiological control of hepatic lipid and cholesterol metabolism is bidirectional with the dietary
input of lipids and cholesterol and hepatic output of the same compounds.
The liver is the central organ in the metabolic regulation of dietary nutrients, including fats
and carbohydrates. Hepatic lipid metabolism is regulated by many inter-dependent pathways: 1)
Acquisition of lipids, including uptake of lipids and fatty acids, and fatty acid synthesis (de novo
lipogenesis). 2) Lipid storage, including triglyceride synthesis and formation of lipid droplets. 3)
Lipid consumption, including fatty acid degradation (lipolysis), β-oxidation, and the secretion of
very-low-density lipoproteins (VLDL) 87. The liver must rapidly adapt to nutritional changes that
occur from a fasted to the fed state by regulating the supply of glucose, ketone bodies, and
lipoprotein triglycerides to peripheral tissues 88.
The liver stores excess glucose as glycogen and excess dietary- and adipose tissue-derived
fatty acids in the form of triglycerides. Under insufficient energy conditions, the liver responds
by increasing β-oxidation of fatty acids, ketogenesis, and synthesis of VLDL. In the fasted state,
the endogenous pathway of lipid metabolism is activated, and hepatic derived lipid is packaged
and transported throughout the body to deliver triglyceride and cholesterol to various cells and
tissues. Non-esterified fatty acids and glycerols are derived from intracellular lipolysis of lipid
droplets from adipose triglycerides, when elevated epinephrine and low insulin levels in circulation
results in activation of hormone-sensitive lipase, and transferred to the liver 88. The glycerol is
absorbed by the liver and converted to glycolytic intermediates (glyceraldehyde-3-phosphate) that
may enter the nonoxidate pentose phosphate pathway. So, in this way, fats can be used for the
synthesis of glucose. The fatty acids are esterified by ATP-dependent acyl-CoA synthetase and
transported into the mitochondria by carnitine palmitoyltransferase I (CPTI) and carnitine
palmitoyltransferase II (CPTII) to enter the β-oxidation pathway in the mitochondrial matrix. β-
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oxidation of fatty acids involves four reactions that cleave two carbons every cycle to form acetylCoA. The cycle begins with the dehydrogenation of fatty acid-CoA creating a trans double bond
between C2 and C3 catalyzed by acyl CoA dehydrogenase using flavin adenine dinucleotide
(FAD) as an electron acceptor to produce trans-Δ-Enoyl CoA. Trans-Δ-Enoyl CoA is hydrated to
produce L-3-Hydroxyacyl CoA.

L-3-Hydroxyacyl

CoA undergoes another dehydrogenation step

using nicotinamide adenine dinucleotide (NAD) as an electron acceptor to produce 3-Ketoacyl
CoA. Acetyl-CoA is produced with the thiolysis of 3-Ketoacyl CoA and the process repeats itself.
The complete oxidation of a 16-carbon palmitoyl-CoA produces 106 adenosine triphosphates
(ATPs).
In addition, to alleviate the energy deficiency with the depletion of glucose, ketone bodies
are produced from acetyl-CoA and are preferentially used as a source of fuel for the cardiac, brain,
and skeletal muscle. Ketone body synthesis converts acetyl-CoA to acetone, acetoacetate, and βhydroxybutyrate. The first step in ketogenesis is the reverse of the thiolase reaction forming
acetoacetyl CoA. Acetoacetyl CoA is converted to β-Hydroxy-β-methyl-glutaryl CoA (HMGCoA) through the action HMG-CoA synthase. Acetoacetate is formed by HMG-CoA lyase from
HMG-CoA followed by spontaneous decarboxylation resulting in acetone. Additionally, βhydroxybutyrate materializes from acetoacetate by the enzymatic activity of β-hydroxybutyrate
dehydrogenase. Ketone bodies, essentially the water-soluble equivalent of acetyl-CoA units, are
transported in the blood to other tissues. Acetone is produced in small quantities and cannot be
converted back to acetyl-CoA, and it is excreted in the urine and exhaled. In target tissues, β hydroxybutyrate is converted to acetoacetate and activated by succinctly CoA-acetoacetate CoA
transferase, an enzyme absent in the liver, resulting in acetoacetyl CoA. A thiolase reaction splits
acetoacetyl CoA into two acetyl-CoA molecules that can enter into the citric acid cycle to produce
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ATP. Ketosis is a state of excess ketone bodies production occurs. Prolonged periods of ketosis
resulting in accumulation of these ketone bodies causes ketoacidosis. Both acetoacetate and βhydroxybutyrate are acidic thus causing the pH of the blood to drop when experiencing prolonged
starvation or in the case of Type I diabetes.
Energy demands of extrahepatic tissues including the heart and skeletal muscle are also
met by the synthesis and secretion of VLDL by the liver providing an endogenous lipid source.
Nascent VLDLs produced in the hepatocyte ER lumen are composed of a triglycerides-rich core
(obtained from adipocytes, chylomicron remnants, or from the intestine via the portal vein),
phospholipids, cholesterol, cholesteryl esters, and specific apolipoproteins

89

. The microsomal

triglyceride transfer protein facilitates the allocation of both neutral and polar lipids to the
developing VLDL.

Apolipoprotein B100 is synthesized in the liver and the major structural

protein of VLDL, which also contain apolipoprotein C (apoC) and apolipoprotein E (apoE). The
VLDL transitions from the ER to the Golgi to prepare for secretion from the hepatocytes via the
coat protein II complex (COPII) on the ER membrane. Once released into circulation, VLDLs
pick up additional apoC from high-density lipoprotein (HDL) particles. Upon arrival at peripheral
tissues, VLDLs are hydrolyzed by lipoprotein lipase, an enzyme bound to the endothelial surface,
through association with apoC. Free fatty acids are released from triglycerides following the action
of lipoprotein lipase which then diffuse into the local tissues to be reassembled into triglycerides
for storage as fat or oxidized to produce ATP. As triglycerides are lost, the VLDL shrinks and
forms an intermediate-density lipoprotein (IDL) containing cholesterol and some triglycerides
with apoB and apoE. Hepatic lipase synthesized by hepatocytes hydrolyzes IDL associated
triglycerides and returns apoC and apoE to HDL converting to low-density lipoproteins (LDL).
LDL contains the only apoB is rich in cholesterol and cholesterol esters representing the route by

37

which cholesterol is transported from the liver to the tissues by receptor-mediated endocytosis to
be used for the synthesis of cellular membranes or steroid synthesis 89. However, most LDL is
recycled and taken up by the liver LDL-receptor, which recognizes and binds apoB.
In the post-prandial state, the liver is central to the regulation of energy supply of glucose,
ketone bodies, lipoprotein, and triglycerides to peripheral tissues.

In the exogenous lipid

metabolism pathway, dietary-derived triglycerides are converted to fatty acids by digestive
enzymes from the pancreas that are activated by bile salts. Bile acids and bile salts are synthesized
in the liver from cholesterol, delivered to the gut for emulsification by the gall bladder, and
subsequently reabsorbed by intestinal cells and returned to the liver for recycling with greater than
95% efficiency. Cholesterol and fatty acids released from dietary lipids are resynthesized into
triglycerides and cholesterol esters in the intestinal mucosal cells and packed into chylomicrons to
be carried through the circulatory system. Chylomicrons pick up apoC and apoE from HDL and
enter the circulatory system through the thoracic duct. Lipoprotein lipase, upon activation by
apoC, is able to hydrolyze triglycerides to free fatty acids and glycerols for transport to target cells.
Free fatty acids are then delivered to muscles cells to be used as an energy source while in adipose
tissue triglycerides are resynthesized and stored. The glycerol component enters the hepatic
glycolytic pathway and the chylomicron remnants, which are enriched in cholesterol, are taken up
by hepatocytes via the interaction between apoE and LDL-receptor-related protein 90.
Liver hepatocytes play a fundamental role in the regulation of biosynthetic synthesis of
fatty acids via hepatic de novo lipogenesis (DNL). Fatty acids play many important biological roles
including being the building blocks for phospholipids and glycolipids, high-energy source of fuel,
and used to build hormones and intracellular messengers. The glycolysis and metabolism of
carbohydrates provide the substrate for DNL. During glycolysis, which takes place in the
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mitochondrial matrix, pyruvate is created and subsequently converted into acetyl-coenzyme A.
The first committed step of fatty acid synthesis begins when malonyl-coenzyme A is synthesized
from acetyl-CoA by acetyl-CoA carboxylase

91

. Malonyl-CoA is covalently linked with the

phosphopantetheine group of an acyl carrier protein (ACP) associated with fatty acid synthase
(FAS) multienzyme complex with subsequent release of the coenzyme A carrier 92. FAS catalyzes
fatty acid chain elongation and the formation of 16 carbon (C16) palmitate first by a condensation
reaction forming acetoacetyl-ACP from acetyl-ACP and malonyl-ACP. Acetoacetyl-ACP then
undergoes a series of reduction and dehydration reactions in the presence of NADPH with the
phosphopantetheine arm of the ACP shuttling the fatty acid chain intermediates from one active
site of the FAS domain to another. This procedure is repeated six more times using malonyl-CoA
as a substrate each time. The FAS thioesterase carries out the chain-terminating step of fatty acid
synthesis by hydrolysis of the acyl-S-phosphopantetheine thioester bond to the ACP domain
resulting in the release of palmitic acid 93. Fatty acid synthesis through DNL is transcriptionally
regulated by sterol regulatory element-binding proteins (SREBPs).
SREBPs are a family of transcription factors that regulate lipid and cholesterol homeostasis
by controlling enzymes required for endogenous synthesis 94. SREBPs are basic-helix-loop-helixleucine zipper (bHLHLZ) transcription factors with three isoforms bound inactively to the ER
membrane.

SREBP-1c controls fatty acid and triglyceride biosynthesis while SREBP-2 is

involved in cholesterol metabolism and LDL receptor expression 95. SREBP1a shows evidence of
being important for both fatty acid and cholesterol pathways. SREBP activation is achieved by
proteolytic cleavage and is coordinated by interaction with SREBP cleavage-activating protein
(SCAP) 96969696and insulin-regulated proteins (Insigs). When cellular sterol is abundant, SREBP
interaction with the SCAP-Insigs complex keeps SREBP tethered to the ER. When sterol level is
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low, or by insulin activation, the SCAP-Insigs association decreases allowing SCAP to position
SREBP at the Golgi, where site-1-protease (S1P) and site-2-protease (S2P) activity processes
SREPBs into active forms. Activated SREBPS are then able to translocate into the nucleus and
bind to the sterol regulatory element of genes involved in lipogenesis and cholesterogenesis

95

.

Failure of SREBP regulation has been implicated in the development of obesity, type 2 diabetes,
dyslipidemia, lipodystrophy, and atherosclerosis.

B.

ER Stress & Lipogenesis
Increasing evidence suggests that the regulation of hepatic lipogenesis is linked to ER stress

and the activity of the UPR. The UPR is comprised of three primary pathways: IRE1α-XBP1,
PERK-ATF4, and ATF6. The ER stress master regulator GRP78/BiP manages the activity of these
pathways by binding to the transmembrane sensors rendering them inactive. Interest grew in the
space as it was determined that the ATF6 pathway might be important in ER stress-induced
lipogenesis as both ATF6 and SREBPs are activated by S1P and S2P 97. Initial studies linking
UPR and hepatic lipid metabolism have reported that GRP78 contribute to hepatic lipogenesis.
GRP78 overexpression in the livers of obese mice inhibits SREBP-1c cleavage and reduces hepatic
triglyceride and cholesterol content 98. Under ER stress, the PERK pathway downregulates the
expression of the Insig protein facilitating SREBP translocation to the Golgi and subsequent
activation

99

.

PERK-mediated phosphorylation of eIF2α yields activation of the CCAAT

enhancer-binding proteins (C/EBP) transcription factors, which promote lipid synthesis via
peroxisome proliferator-activated receptor γ (PPARγ) expression 100 It also has been reported that
ATF4 is associated with ER stress-induced lipogenesis as ATF deficiency is protective for hepatic
steatosis by downregulation of stearoyl-CoA desaturase (SCD) expression 101. The IRE1α-XBP1
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pathway has been shown to regulate genes involved in the fatty acid synthesis, including C/EBPβ
102

. Through IRE1α null mice experiments, IRE1α has been identified as an important player in

repressing hepatic lipid accumulation and maintaining efficient secretion of VLDL and LDL from
hepatocytes under conditions of ER stress 54. Downstream of IRE1α, selective XBP1 deletion in
hepatocytes results in a hypotriglyceridemia and hypocholesterolemia condition with a marked
decrease in the production of lipids 96. Similar to IRE1α, ATF6-knockout mice under conditions
of ER stress display more severe liver injury and steatosis ascribed to the suppression of VLDL
formation and the inhibition of fatty acid β-oxidation 103.
A downstream target of all three UPR signaling pathways, CHOP has been identified as a
contributing factor in the ER stress-induced dysregulation of lipid metabolism. Under cholestatic
conditions, CHOP-deficient mice displayed attenuated liver fibrosis and apoptotic/necrotic
hepatocyte death 104.
VI. Liver
A.

Liver Organization
The liver is the largest visceral organ in humans and other higher vertebrates accounting

for 2-3% of average body weight. The liver is an essential organ in maintaining homeostasis by
managing metabolic functions and immunogenic responses. The liver accomplishes this by
synthesizing numerous vital molecules, detoxifying chemicals, neutralizes foreign antigens and
metabolizes xenobiotics entering through the gastrointestinal tract 88. In adult humans, the liver is
comprised of two lobes differentiated both morphologically and functionally 105. The left and right
hepatic lobes are both comprised of a continuous sponge-like parenchymal mass penetrated by
tunnels that contain afferent and efferent vessels
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88

. The liver is a particularly vascular organ

receiving up to 25% of total cardiac output at rest, more than any other organ, with dual
contributions from the hepatic artery and the portal vein at 30% and 70% of blood supply
respectively

105

. These blood vessels are surrounded by connective tissue making up the portal

tracts that also serves as a channel for bile ducts, lymphatic vessels, nerves and nonparenchyma
cells. The portal vein provides the bulk of the nutritive supply to the liver receiving blood draining
from the gastrointestinal tract, as well as the pancreas, gallbladder, and spleen. The terminal
branches of the portal vein, the hepatic arterioles, and the common bile duct, form the hepatic
portal triad and empty into the hepatic sinusoids for the blood to be processed by the hepatocytes
before exiting the liver by the hepatic veins and eventual distribution throughout the body.
B.

Hepatic Cells
The major cells of the liver include hepatocytes, cholangiocytes, sinusoidal endothelial

cells, KCs, stellate cells, and immune cells such as lymphocytes and dendritic cells. Hepatocytes
are the major parenchymal cells in the liver making up 80% of the total liver volume and play
pivotal roles in carbohydrate, fat, and protein metabolism.

Additionally, the multiplicity of

functions of hepatocytes includes the production and secretion of bile acids, cholesterol, and
steroid hormone synthesis, detoxification of drugs and other toxic compounds, and secretion of
clotting factors. A large fraction of the hepatocyte cell volume is taken up by organelles that reflect
the underlying functional capacity.

The distribution of hepatocyte organelles includes an

abundance of mitochondria fulfilling cell energy requirements for protein synthesis, a vast array
of peroxisomes and lysosomes performing detoxification and providing enzymes that facilitate
catabolic and anabolic reactions in the liver (i.e. fatty acid synthesis), Golgi complexes for
modifying and sorting proteins and lipids for secretion, and a sizeable amount of aggregates of
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smooth and rough ER- representing nearly 15% of cell volume- executing protein synthesis and
lipid metabolism functions.

C.

Drug-Induced Liver Injury
In developed countries, adverse drug reactions are a leading cause of death with

hepatocellular death and acute liver failure being the most common complication33, 106. Druginduced liver injury (DILI) remains a hot topic among academics, biotech and pharmaceutical
companies, and clinicians as an expanse of literature has become available over the last several
years. DILI has become increasingly important as researchers consider pharmaceutical and healthcare economics. In 2014, The Tufts Center for the Study of Drug Development (TCSDD)
published a report detailing the cost per new prescription drug approval at a stunning $2.6 billion.
DILI is the main cause of the withdrawal of an approved drug form the market or discontinuation
of clinical trials of potential drug candidates thus resulting in a significant financial loss.

The

National Center for Toxicological Research (NTCR), a branch of the United States Food and Drug
Administration, has published a database consisting of the 1,036 FDA-approved drugs that are
reviewed on the basis of their potential for causing DILI with over 45% of the listed compounds
scoring a “DILI-concern” notation. DILI results from either intrinsic direct damage to the liver in
a dose-dependent manner or idiosyncratically by immunological mechanisms
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. Direct dose-

dependent hepatotoxic effects are documented for many drugs including anti-infective, neurologic
or pain modifying substances i.e. acetaminophen

107

. The intrinsic hepatotoxic effect of the

painkiller acetaminophen (APAP) is an extensively studied example and the most common cause
of DILI in developed countries 108. APAP is widely used in the USA and the single leading cause
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of calls to poison control centers and subsequent APAP-related emergency room visits and
hospitalization. Like most drugs, APAP, is primarily metabolized in the liver. Therefore, failure
to resolve APAP toxicity may result in acute liver failure (ALF) and ultimately death.
Idiosyncratic DILI (IDILI) occurs in a small population of individuals following drug exposure
and a latency period. IDILI is characterized as being an unpredictable and a mostly doseindependent occurrence. Due to a wide range of clinical presentations and lack of diagnostic
markers, IDILI becomes a diagnosis by exclusion for physicians in cases of unexplained liver
injury 33. The pathophysiology of IDILI is multifactorial involving genetic and nongenetic host
susceptibility. Genetic risk factors causing a predisposition to IDILI include polymorphisms
affecting various drug-metabolizing enzymes (Phase I and Phase II), drug transporters, ROSreducing enzymes, and immunologic processes
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. Nongenetic risk factors include underlying

comorbidities include pre-existing conditions of chronic liver diseases including hepatitis B or C,
human immunodeficiency virus 110, ALD, nonalcoholic fatty liver disease (NAFLD), nonalcoholic
steatohepatitis (NASH), or primary biliary cholangitis (PBC). Other nongenetic factors include
age, sex, daily dose, drug interactions, alcohol, and metabolism profile.

METHODS & MATERIALS
Reagents
RAW 264.7 macrophage-like cells were purchased from Sigma-Aldrich (St. Louis, MO).
Fetal Bovine Serum (FBS) was obtained from Atlanta Biologics (Flowery Branch, GA) and was
heat-inactivated for 30 minutes at 65°C. Nile red, Oil Red O, and common chemical reagents
were purchased from Sigma Aldrich (St. Louis, MO). The mice were fed ad libitum a standard
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mouse chow diet purchased from Bio-Serv (Flemington, NJ). Antibodies against activating
transcription factor (ATF)-4, X-box-binding protein (XBP)-1, C/EBP Homologous Protein
(CHOP), Lamin B, horseradish peroxidase-conjugated goat anti-rabbit IgG and horseradish
peroxidase-conjugated donkey anti-goat IgG were purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA) 111. Mouse monoclonal antibody against β-actin was from Thermo Fisher
(Waltham, MA). Bio-Rad protein assay reagent and Precision Plus Kaleidoscope standards were
acquired from Bio-Rad Laboratories (Hercules, CA) 112. The ApoAlert Annexin V kit was from
BD Biosciences (San Jose, CA). Kaletra® (lopinavir/ritonavir coformulation) was obtained from
AbbVie (North Chicago, IL).
Cell Culture
The RAW 264.7 macrophage-like cell line were maintained in DMEM supplemented with
10% FBS and 10% penicillin/streptomycin and incubated at 37°C with 5% CO2. Cells were plated
at 1.2 x106 cells per plate (60-mm) and cultured overnight. Cells were treated with dimethyl
sulfoxide (DMSO) as vehicle control, HIV PIs (lopinavir and ritonavir), ethanol at different
concentrations (50, 100 mM), and LPS (50 ng/mL) for a different time period (0-24 hour)
Mice
Both C57BL/6J mice and CHOP global knockout mice (CHOP-/-) obtained from Jackson
Laboratory were used for this study.

All experiments and procedures were approved by

Institutional Animal Care and Use Committee of Virginia Commonwealth University. The
researcher completed annual training on the responsible care and use of animal subjects. The
animal care program at VCU complies with all Federal and State laws regarding the use and care
of experimental animals, and with Public Health Service Policy on Humane Care and Use of
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Laboratory Animals (NIH Guide for Grants and Contracts, Vol. 14, No. 8, June 25, 1985). The
American Association for Accreditation of Laboratory Animal Care (AAALAC) currently
accredits the facilities and care program. Animals will be kept under full-time veterinary
supervision.
Isolation and Culture of Primary Hepatocytes
Rat primary hepatocytes and mouse primary hepatocytes were isolated from adult male
Sprague-Dawley rats and C57BL/6 mice (both wild type and CHOP-/-), respectively using the
collagenase-perfusion technique of Bissell and Guzelian 113. The cells were cultured in serum-free
Williams’ E medium with dexamethasone (0.1μM), penicillin (100 units/mL), thyroxine (1μM).
The cells were incubated for in 5% CO2 environment at 37°C for 4 hours followed by treatment
with vehicle control, DMSO, HIV PIs (Lopinavir/Ritonavir, 4:1, 25μM) without or with different
amount of ethanol (50, 100, 200 mM) for 0 to 24 h.
Animal studies
In preparation for chronic ethanol feeding with HIV PI we secured C57BL/6J and
CHOP-/- mice from the Jackson Laboratory. All experiments involving mice were approved by
Institutional Animal Care and Use Committee of Virginia Commonwealth University and were in
accordance with procedures to ensure compassionate care and comfort 111. To investigate the role
of ethanol- and HIV PI- induce hepatic lipotoxicity, male wild type and CHOP-/- mice aged 8-12
weeks were randomly assigned to four groups: 1) Control (0.2% sodium carboxymethyl cellulose,
CMC-Na), 2) Ethanol (2.5 g/kg), 3) Lopinavir/Ritonavir 4:1 (50 mg/kg), and 4)
Lopinavir/Ritonavir + Ethanol.
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Figure 6. Oral gavage feeding schematic. Wild type or CHOP-/- were administered alcohol and
HIV PI by oral gavage.

All mice were housed under identical conditions in a sterile mouse facility with access to
water and a standard diet 111. The oral gavage treatment solutions were prepared with CMC-Na
as a solvent and administered daily for 8 weeks. The mice were weighed daily to adjust drug
intake. At completion of the 8-week treatment period, the mice were fasted for 6 hours and liver
tissues were harvested for downstream analysis.
RNA Isolation and qRT-PCR
Total RNA was extracted from rodent hepatocytes using the TRIzol (Invitrogen) reagent
extraction. The treated cells were rinsed with cold PBS and the then lysed in a culture dish with
700 μl of TRIzol reagent by scraping the dish with a cell scraper. The cell lysate was transferred
to a 1.5mL microfuge tube and vortexed for homogenization and incubated at room temperature
for 5 minutes. 200 ul of chloroform was added to the cell lysate and the tubes were shaken
vigorously by hand for 15 seconds then incubated at room temperature for 5 minutes. The samples
were centrifuged at 12,000 x g for 15 minutes at 2-8°C to separate the phenol-chloroform and

47

aqueous phases. The RNA from the aqueous phase was precipitated by mixing with the same
volume isopropyl alcohol to the aqueous phase and incubated at room temperature for 10 minutes.
After centrifugation at 12,000 x g for 10 minutes at 2-8°C, the supernatant was removed and the
RNA pellet was washed with 1mL of 75% ethanol, vortexed, and centrifuged at 7500 x g for 5
minutes at 2-8°C. The RNA pellet was air-dried for 5-10 minutes with care not to let the RNA
pellet dry completely as this will greatly decrease solubility. The RNA pellet is dissolved in 65 μl
of PCR water by passing the solution through a pipette tip and incubated for 10 minutes at 5560°C. The RNA concentration was analyzed by UV absorbance using 1.5μL of diluted RNA
sample in a NanoDrop 2000C spectrophotometer. The optical density was measured at 260 nm
and 280 nm to determine sample concentration and purity. The A260/A280 ratio was required to be
>1.6, with optimal A260/A280 to be >1.8. For liver tissue RNA isolation, 50 mg of liver samples
were homogenized in 1mL of TRIzol using a glass tissue grinder. The RNA isolation procedure
is identical following tissue homogenization. Total RNA (2 μg) was used for the first-strand cDNA
synthesis using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The
cDNA samples were diluted to 2 ng/μl for real-time PCR analysis using iQTM SYBR Green
Supermix (Bio-Rad #170-8882) qRT-PCR master mix product.
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Table III. High-Capacity cDNA Reverse Transcription Kit. cDNA RT-PCR reagent kit
recipe to synthesize single-stranded cDNA from total RNA.

Component

Volume per reaction

Concentration

(μl)

10X Buffer

2

dNTP

0.8

Random Primers

2

RNAse Inhibitor

0.5

Transcriptase

1

H2O

3.7

Total

10

Table IV. iQTM SYBR Green Supermix. Recipe for qRT-PCR analysis using IQTM.

Component Concentration

Volume per reaction (μl)

iQTM SYBR Green Supermix 2X

10

Primer 1 (10 μM)

0.1

Primer 2 (10 μM)

0.1

Sterile water

4.8

DNA template

5

Total

20
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Following qRT-PCR, the relative mRNA level for each gene was normalized to internal
control GAPDH or HPRT1 and compared with vehicle control.
Western Blot analysis
Nuclear and total protein lysates were prepared from primary rat or mouse hepatocytes.
Plated cells were washed with cold PBS. The PBS was aspirated, and the lysis buffers were added
to the culture dishes. The total lysis proteins were isolated with RIPA reagent (20mM Tris-HCl,
150 mM NaCl, 2 mM EDTA, 20 mM NaF, 1 mM NaVO4, 1% NP-40, and 0.1% SDS, pH 8.0).
For nuclear cell lysis, the protein was isolated with Buffer A (10 mM Hepes, 10 mM KCl, 0.1 mM
EDTA, 0.1 mM EGTA, 2 mM NaF, 2 mM Na3VO4, protease inhibitor). After the addition of
buffer A, adherent cells were scraped with a cell scraper and the cell solution was transferred to a
microfuge tube and stored overnight at -20°C. Cell solutions were thawed and 12.5 μl of NP-40
(10%) to each sample, vortexed, and kept on ice for 30 minutes. Samples underwent a strong
vortex for 3 minutes and centrifuged for 10 minutes at 14,000 rpm at 4°C.

Following

centrifugation, the cell supernatant was aspirated and transferred into another tube as the cytosolic
protein fraction. The remaining cell pellet, representing the nuclear protein fraction, solubilized
with buffer B (20 mM Hepes, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 2 mM NaF, 2 mM Na3VO4,
protease inhibitor) and vortexed to assure suspension. After a freeze-thaw cycle, the cell solution
was placed in strong vertex for 3 minutes and centrifuged at 4°C at 4,000 rpm for 10 minutes
placing the cell junk in a pellet and the purified nuclear fraction suspended in the supernatants.
For nuclear, cytosolic, and total protein sample preparation a small volume of lysate was used to
determine protein concentration with the Bio-Rad Protein Assay Dye Reagent Concentrate (Cat.
#5000006). Western blot samples were prepared using 4X Laemmli sample buffer. After
denaturing by boiling for 15 minutes, samples were resolved on 10% SDS-PAGE gel and
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transferred to nitrocellulose membranes. The membrane was blocked with 5% nonfat milk in Trisbuffered saline buffer at 4°C followed by incubation with antibodies for proteins of interest
overnight. The membrane was washed with Tris-buffered saline with 0.5% Tween® 20 and
incubated with the appropriate secondary antibody. The membranes were analyzed with Bio-Rad
ChemiDoc™ MP Imaging System.
Nile Red and Oil Red O Staining of Intracellular Lipids
-/-

Wild type and CHOP mouse hepatocytes were plated in 12-well plates. The medium was
replaced after 4 hours, and the cells were treated with DMSO vehicle control, HIV PI, and/or
alcohol for 24 hours. The cells were fixed with 3.7% formaldehyde/PBS for 30 min followed by
two washes with PBS. The cells were stained with 0.2% Oil Red O in 60% 2-propanol for 10
minutes and detected by microscopy under a 40 x lens. Primary hepatocytes were also stained
with Nile Red (10 µg/ml) for 60 minutes and washed three times with PBS

112

and detected by

fluorescent microscopy under a 40 x lens.
Statistical Analysis
All in vitro experiments were repeated at least three times and results were expressed as
the mean ± SE of three experiments. One-way ANOVA analysis of variance was employed to
analyze the differences between different treatments.
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Chapter I:

HIV Protease Inhibitors and Alcohol Promotes Hepatotoxicity by Activation
of the Unfolded Protein Response

Study Rationale
With the accelerated progression of the AIDS epidemic since HIV was identified as the
causative agent in 1987, researchers have focused attention on elucidating HIV pathophysiology
and identifying pharmacological agents to target the HIV life cycle. The development of the
HAART treatment spawning from the usage of multiple classes of anti-HIV therapeutics proved
to be the most effective and widely used care management plan. HIV PIs remain the cornerstone
of HAART, and introduction into the treatment strategy has changed HIV infection from an
invariably lethal to a manageable chronic condition. Despite the clinical successes of HIV PIs,
accumulating clinical evidence suggests that the HIV PI-based drug regimen is associated with
severe hepatic lipotoxicity, which often results in interruption or discontinuation of the therapy 114,
115

. In a similar fashion, alcohol abuse is found to be very common among PLWHA, contributing

to the occurrence of metabolic syndrome and HAART discontinuation. Despite the prevalence of
this problem and its serious impact on the quality of life and continued therapy in HIV patients,
the cellular mechanisms by which alcohol exacerbates HAART-induced hepatic lipotoxicity
remain to be identified. The previous studies in Dr. Huiping Zhou’s laboratory has shown that
activation of the ER stress by HIV PIs results in hyperlipidemia in macrophages, adipocytes, and
hepatocytes

112, 116, 117

. Additionally, Dr. Zhou’s laboratory has demonstrated that the use of

pharmacological agents to reduce ER stress has the potential to attenuate HIV PI-induced
dysregulation of hepatic lipid metabolism 118.
The burden of liver injury in HIV patients is expected to increase as the number patients
living HIV continues to rise. Chronic alcohol consumption further exacerbates HIV PI-induced
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liver injury. The goal of the present study is to identify the potential cellular mechanisms
underlying alcohol and HIV PI-induced hepatic lipotoxicity and provide new information for the
development of new preventative and therapeutic strategies for alcohol and HAART-associated
liver diseases.
Results
HIV PIs and alcohol activate the UPR in rat primary hepatocytes in a timedependent manner
The adverse effects of HIVPIs are well documented in contributing to hyperlipidemia,
hypercholesterolemia, and hepatotoxicity. Similarly, chronic and acute alcohol consumption, a
common risk factor for liver diseases, produces a wide spectrum of clinical presentations
including steatosis and hepatic injury. Our previous studies have shown unresolved ER stress as
an important mechanism for HIV PI-induced disruption of lipid homeostasis in hepatocytes. To
determine the direct effect of alcohol on HIV PI-induced toxicity, individual HIV PIs were used
to treat primary rat hepatocytes with or without ethanol (150 mM) for 24 h and the cell viability
was determined by MTT assay. As shown in figure 7, consistent with the previously published
results, HIV PIs had a differential effect on cell viability and addition of alcohol further
increased the toxicity induced by HIV PIs, especially for lopinavir (LOPV), ritonavir (RITV),
Nelfinavir (NEV), saquinavir (SQV) effect on HIV PI-induced toxicity.
The U.S. Department of Health and Human Services (DHHS) Guidelines for Use of
Antiretroviral Agents in HIV-1 infected Adults and Adolescents recommends the
lopinavir/ritonavir (L/R) coformulation as a preferred regimen as initial treatment as well as for
treatment-experienced patients. In order to determine whether alcohol further promotes HIV PI-
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Figure 7. Effect of alcohol and HIV PIs on cell viability in primary rat hepatocytes. Rat
primary hepatocytes were treated with dimethyl sulfoxide (DMSO) vehicle control, or individual
HIV PIs (25 µM), Amprenavir (AMPV), Lopinavir (LOPV), Ritonavir (RITV), Nelfinavir
(NEV), Atazanavir (ATZV), Saquinavir (SQV) or Indinavir (IDV), without or with alcohol
(ETOH, 150 mM) Cell viability was measured by a CCK-8 assay. Data are presented as the
mean ± SE of three experiments. Statistical significance, *p<0.05, **p<0.01, ***p<0.001,
compared to DMSO group; #p<0.05, ##<0.01, ###p<0.001, compared to the corresponding HIV
PI group without ETOH.
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induced ER stress in hepatocytes, rat primary hepatocytes were isolated and plated for overnight.
Cells were treated with L/R (25 µM) alone or with various concentration of alcohol (0, 50, 100,
200 mM) for different time periods (0, 3, 6 and 24 h). The expression levels of the UPR genes
(ATF4, XBP1s, XBP-1u, and CHOP) were determined by real-time RT-PCR analysis using
GAPDH as an internal control. As shown in figure 8-11, both alcohol and L/R time-dependently
induced the UPR gene expression, the most significant changes were observed at 6 h time point.
Optimization of experimental design and characterization of HIV PIs and alcohol
on the activation of the UPR in rat primary hepatocytes
After reviewing a time-course for UPR activation in rat primary hepatocytes, we attempted
to optimize the experimental design to reduce the variance and increase reproducibility. As shown
in figures 8-11, L/R and alcohol activated the UPR in hepatocytes after culturing for 3-6 hours.
As HIV PIs are rapidly metabolized in hepatocytes, we selected the 6 hours time-point for the
following studies. Our initial experiment was carried out after overnight plating of the isolated of
primary hepatocytes. However, we noticed that the extended culture of the primary rodent
hepatocytes resulted in the significant downregulation of the key genes related to lipid metabolism.
Therefore, we changed our experimental protocol and started the treatment 4 h after cells were
plated and attached 119. As shown in figure 12, L/R and alcohol significantly activated the UPR.
To further examine the effect of alcohol and L/R on the protein expression of the UPR
components, rat primary hepatocytes were treated with L/R (25 µM) with or without alcohol (200
mM) for 6 h, the nuclear proteins were isolated. The protein levels of CHOP, XBP-1, and ATF4
were measured by Western blot analysis and lamin B was used as a loading control. As shown in
figure 13, alcohol significantly increased L/R-induced CHOP, ATF4 an XBP-1 expression in rat
primary hepatocytes.
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Figure 8. HIV PIs and alcohol time-dependently induced ATF4 expression in rat primary
hepatocytes. Rat primary hepatocytes were isolated and plated for overnight and then treated with
vehicle control (DMSO), (L/R) (25 μM), or L/R with different amount of ETOH (0, 100 or 200
mM) for 1, 3, 6 or 24 h. Total cellular RNA was isolated and the mRNA levels of ATF4 were
quantified by real-time RT-PCR and normalized using GAPDH as an internal control. Values are
mean ± SE of three independent experiments. Statistical significance relative to vehicle control,
*p<0.05, and **p<0.01.
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Figure 9. HIV PIs and alcohol time-dependently induced XBP-1s expression in rat primary
hepatocytes. Rat primary hepatocytes were isolated and plated for overnight and then treated with
vehicle control (DMSO), (L/R) (25 μM), or L/R with different amount of ETOH (0, 100 or 200
mM) for 1, 3, 6 or 24 h. Total cellular RNA was isolated and the mRNA levels of XBP-1s were
quantified by real-time RT-PCR and normalized using GAPDH as an internal control. Values are
mean ± SE of three independent experiments. Statistical significance relative to vehicle control,
*p<0.05, and **p<0.01.
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Figure 10. HIV PIs and alcohol time-dependently reduced XBP-1u expression in rat primary
hepatocytes. Rat primary hepatocytes were isolated and plated for overnight and then treated with
vehicle control (DMSO), (L/R) (25 μM), or L/R with different amount of ETOH (0, 100 or 200
mM) for 1, 3, 6 or 24 h. Total cellular RNA was isolated and the mRNA levels of XBP-1u were
quantified by real-time RT-PCR and normalized using GAPDH as an internal control. Values are
mean ± SE of three independent experiments. Statistical significance relative to vehicle control,
*p<0.05, and **p<0.01.
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Figure 11. HIV PIs and alcohol time-dependently induced CHOP expression in rat primary
hepatocytes. Rat primary hepatocytes were isolated and plated for overnight and then treated
with vehicle control (DMSO), (L/R) (25 μM), or L/R with different amount of ETOH (0, 100 or
200 mM) for 1, 3, 6 or 24 h. Total cellular RNA was isolated and the mRNA levels of CHOP
were quantified by real-time RT-PCR and normalized using GAPDH as an internal control.
Values are mean ± SE of three independent experiments. Statistical significance relative to
vehicle control, *p<0.05, and **p<0.01.

59

Figure 12. HIV PIs and alcohol-induced activation of the UPR in rat primary hepatocytes at
6 h time point. Rat primary hepatocytes were isolated and plated for 4 h. After refresh the
medium, cells were treated with vehicle control (DMSO), L/R (25 μM) with or without alcohol
(ETOH, 100 or 200 mM) for 6 h. Total cellular RNA was isolated, and the mRNA levels of UPR
genes after 6 (Bip/GRP78, ATF4, CHOP, XBP-1s, and XBP-1u) were quantified by real-time RTPCR and normalized using internal control GAPDH. Values are mean ± SE of three independent
experiments, which were performed in triplicate. Statistical significance relative to vehicle
control, *p<0.05, **p<0.01, ***p<0.001.
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Figure 13. Effect of alcohol on L/R-induced UPR activation in rat primary hepatocytes.
Rat primary hepatocytes were treated with DMSO or L/R (25 µM) with or without alcohol
(ETOH, 200 mM) for 6 h. The nuclear proteins were isolated. The protein levels of CHOP,
ATF4, and XBP-1 were determined by Western blot analysis. Lamin B was used as a loading
control for nuclear protein. A. Representative immunoblot images of CHOP, XBP-1, ATF-4,
and Lamin B are shown. B-D, the relative protein expression levels were determined and
normalized to Lamin B. Results are represented as mean ± SE from three experiments.
Statistical significance relative to DMSO group, *p<0.05, **p<0.01; Statistical significance
relative to L/R group, #p<0.05.
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Effect of Alcohol on L/R-induced UPR activation in mouse primary hepatocytes.
The previous study from Dr. Zhou’s lab showed that CHOP played a critical in HIV PIinduced hepatic lipotoxicity. As a major transcription factor mediating the ER stress-induced
apoptosis, down-regulation of CHOP expression has been shown to have a protective effect against
ER stress-induced cell injury 120. To further determine the impact of alcohol on HIV PI-induced
ER stress activation in hepatocytes, the primary mouse hepatocytes were isolated from both wildtype and CHOP-/- mice and treated with DMSO, or L/R (25 µM) with or without alcohol (ETOH,
0, 100 or 200 mM) for 6 h. The mRNA levels of CHOP, ATF4, and XBP-1 were determined by
RT-PCR. As shown in figure 14, L/R alone significantly upregulated the mRNA levels of CHOP,
ATF and XBP1, which was further increased by alcohol in wild type mouse primary hepatocytes.
However, in the absence of CHOP, both L/R and alcohol had no effect on XBP-1 expression.
Although the combination of L/R with alcohol (200 mM) still induced ATF4 expression in CHOP/-

mouse hepatocytes, but to a less extent compared to that in wild type mouse primary hepatocytes.
In line with the real-time PCR results, the western blot analysis also showed that L/R and

alcohol significantly increase the protein levels of CHOP, ATF4, and XBP-1 in wild-type mouse
primary hepatocytes. However, both L/R and alcohol-induced ATF4 and XBP-1 expression were
similar in the CHOP-/- mouse primary hepatocytes as that in wild type mouse primary hepatocytes
(Figure 15). Since CHOP is the downstream signaling molecule of the ATF4 and XBP1, the
deletion of CHOP has no significant effect on ATF4 and XBP1 expression. However, in our in
vivo studies with 8-weeks alcohol and HIV PI treatment, western blot analysis of whole liver
lysates reveals an upregulation in XBP1 protein expression in wild type mice with HIV and alcohol
compared to that seen in CHOP-/- mice (Figure 16).
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Figure 14. Effect of HIV PIs and alcohol treatment on UPR activation in wild-type and
CHOP-/- mouse primary hepatocytes. Wild-type and CHOP-/- primary hepatocytes were isolated
and treated with vehicle control (DMSO) or L/R (25 μM), with or withour alcohol (EtOH, 100 or
200 mM) for 6 h. Total cellular RNA was isolated and the mRNA levels of ATF4, CHOP, and
XBP1s were quantified by real-time RT-PCR and normalized using internal control GAPDH.
Values are mean ± SE of three independent experiments. Statistical significance relative to vehicle
control, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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Figure 15. The effect of HIV PIs and alcohol on the UPR activation in wild-type and
CHOP-/- mouse hepatocytes. Mouse primary hepatocytes isolated from the wild-type and
CHOP-/- mice were treated with DMSO or L/R (25 μM) with or without alcohol (EtOH, 100 or
200 mM) for 6h. The total cell lysate was isolated. The protein levels of CHOP, ATF4, XBP1,
and GRP78 were detected by Western blot analysis and actin was used as a loading control. The
representative immunoblot images are shown.
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Figure 16. In vivo effect of HIV PIs and alcohol treatment on UPR activation in wild-type
and CHOP-/- mouse livers. Wild-type and CHOP-/- mouse livers isolated and treated with
vehicle control (Sodium Carboxymethyl Cellulose, Na-CMC) or L/R (50 mg/kg), with or without
alcohol (ethanol, 2.5 g/kg) for 8 weeks. The nuclear and total cell lysate was isolated. The
protein levels of CHOP, ATF4, XBP1, and BiP/GRP78 were detected by Western blot analysis
with Lamin B and actin used as a loading controls.
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Significance
The HAART remains the most effective treatment available for HIV/AIDS patients with
HIV PIs maintained as a key component for the foreseeable future. As HIV PIs have proven
effective in successfully reducing viral loads and significantly reducing mortality rates, the number
of individuals living with HIV/AIDS has greatly increased since the epidemic began

121

.

Additionally, global efforts with governmental partnerships have facilitated easier access to
antiretroviral drugs and monitoring of treatment adherence and outcomes 122. Unfortunately, as a
result of earlier initiation and lifelong exposures to antiretrovirals, hepatotoxicity has become of
particular concern in the clinic123.
Substance abuse, especially chronic alcohol consumption, presents serious therapeutic
challenges including drug-drug interactions, reduction in patient adherence and discontinuation of
drug treatment 124. The liver is a site of first pass metabolism of alcohol and drug compounds with
misuse resulting in liver damage. Alcohol dependence is a common precursor to liver cirrhosis
and is especially destructive in conjunction with other hepatotoxic agents. Alcohol abuse has been
identified as a risk factor impacting PI-based HAART-induced severe hepatocellular injury
characterized by the disruption of normal cellular function including metabolic processes.
ER stress has been identified as an important feature underlying HIV PI-induced
hepatotoxicity. Furthermore, clinicians have noticed that alcohol consumption is associated with
increased liver injury in HIV patients under HAART. Yet, little is known about the mechanistic
pathways by which alcohol promotes HIV PI-induced hepatotoxicity.

Efforts towards

understanding the cellular mechanisms by which alcohol and HIV PI contribute to liver injury may
provide useful drug development strategies and clinical approaches advancing current therapies.
Our lab previously demonstrated several HIV PIs were able to induce UPR activation and ER
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stress with provocation of the pro-apoptotic transcription factor CHOP in macrophages,
hepatocytes, and total liver isolates. In the present study, we hypothesized that the additive effects
of alcohol and HIV PIs would prompt UPR activation and ER stress. Our results show that the coadministration of alcohol and HIV PIs induced UPR activation, ER stress, and CHOP upregulation
in murine, rat, and human hepatocytes. Additionally, it was shown in CHOP-/- murine primary
hepatocytes that ATF4 and XBP1s remain elevated with alcohol- and HIV PI- stimulation.
Chapter II: Effect of HIV PIs and Alcohol on Hepatic Lipotoxicity
Study Rationale
Unresolved ER stress has been linked to the dysregulation of hepatic lipogenesis and
metabolic diseases such as diabetes, obesity, and cardiovascular disease. The ER-rich liver is the
central metabolic organ responsible for fatty acid and cholesterol metabolism. With the ER being
the primary site of lipid metabolism, several factors that regulate lipid homeostasis are found in
the ER. The UPR has been implicated as a potential signaling mechanism in the regulation of
hepatic lipogenesis as key enzymes, and lipogenic factors are significantly upregulated with
increased activation of the various components of the UPR signaling pathway

125

. ER stress-

inducible lipogenic factors have been described as an underlying mechanism for HIV PI-based
HAART-associated metabolic complications.
Our studies have previously shown the differential effects of individual HIV PIs on the
activation of the ER stress, which are linked to the subsequent HIV PI-induced hepatic
dyslipidemia 116. Ritonavir was shown to be a strong activator of the UPR, leading to induction of
hepatocyte apoptosis, activation of the SREBPs and suppression of CYP7A1 expression in rodent
hepatocytes. This finding correlates with ritonavir administration leading to increased clinical
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incidences of adverse metabolic effects, including insulin resistance, lipodystrophy, and
hyperlipidemia in HIV patients 126. As such, it became evident as to the necessity of ritonavir to
be relegated to primary usage as a pharmacoenhancer of other HIV PIs. The L/R is the most
commonly used HIV PIs in HAART. Prolonged activation of the ER stress and elevated CHOP
expression contribute to several pathological conditions in the liver including DILI, lipotoxicity,
and cholestasis. Several studies have linked fatty acid-mediated ER stress and increased CHOP
expression with ultimate activation of hepatocyte cellular apoptosis pathways and liver injury 127129

. Our laboratory has previously identified CHOP as a key player linking ER stress and HIV PI-

induced hepatic lipotoxicity 111. Both in vitro and in vivo studies depicted that HIV PIs, especially
L/R significantly increased hepatic lipid accumulation and liver injury, which was reduced
considerably by deletion of CHOP 111. It has been well-established than ER stress is also involved
in alcohol-induced hepatic lipid accumulation and liver injury. As alcohol is commonly abused
by HIV-1 infected patients, a comorbid risk factor for disruption of hepatic lipid metabolism.
However, the effect of alcohol on HIV PI-induced dysregulation of hepatic lipid metabolism
remains to be identified and is the focus of the current study.
Results
HIV PIs and alcohol disrupts lipid homeostasis in rat primary hepatocytes
Activation of ER stress has been liked to various metabolic diseases including fatty liver
diseases and drug-induced liver injury. To further examine the effect of alcohol and HIV PIs on
hepatic lipid accumulation, rat primary hepatocytes were treated with DMSO or HIV PIs (LOPV
or RITV, 25 µM) with or without alcohol (ETOH, 0- 120 mM) for 24 h. The intracellular lipid
was stained with Nile red and analyzed by fluorescent microscopy. As shown in Figure 17, both
RITV and LOPV significantly induced lipid accumulation. Alcohol alone also dose-dependently

68

increased intracellular lipid accumulation. However, the combination of LOPV or RITV with
alcohol further increased lipid accumulation, especially with 120 mM ETOH.
To further examine the effect of the lopinavir/ritonavir coformulation with alcohol on lipid
accumulation in hepatocytes. Rat primary hepatocytes were treated with DMSO or L/R ( 25 µM)
with or without ETOH (0, 50, 100 or 200 mM) for 24 h. The intracellular lipid was stained with
nile red.

As shown in figure 18,

ETOH dose-dependently promoted L/R-induced lipid

accumulation in rat primary hepatocytes.
Effect of CHOP on alcohol and HIV PI-induced hepatic lipid accumulation.
To further delineate the role of ER stress and CHOP in alcohol and HIV PI-induced hepatic
lipid accumulation, mouse primary hepatocytes isolated from wild type and CHOP-/- mice were
treated with L/R (25 µM) with or without ETOH (0, 100 or 200 mM) for 24 h. The intracellular
lipid was stained with Oil Red O as previously described. As shown in figure 19, L/R-induced
lipid accumulation was significantly increased by ETOH in wild type (WT) mouse primary
hepatocytes, but not in CHOP-/-

mouse primary hepatocytes. As previously described, we

performed in vivo studies with oral gavage of wild type and CHOP-/- mice for 8-weeks. H&E
staining of isolated wild type and CHOP-/- mouse livers following completion of the study showed
marked increase in lipid accumulation in wild type mice compared to CHOP-/- in response to L/R
and alcohol as evidenced by macrovesicular steatosis demonstrated by large white vacuoles
(Figure 20).
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Figure 17. Alcohol and HIV PIs induced lipid accumulation in primary rat hepatocytes. Rat
primary hepatocytes were treated with either 25μM ritonavir or lopinavir with or without various
amounts of alcohol (0, 25, 60 or 120 mM) for 24 hours. Cellular lipids were stained by nile red
and detected by fluorescent microscopy. Representative images are shown.
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Figure 18. Effect of alcohol on L/R-induced lipid accumulation in rat primary hepatocytes.
Rat primary hepatocytes were treated with L/R coformulation (25μM) without or with ETOH (0,
50, 100 or 200 mM) for 24 h. Cellular lipids were stained by nile red and detected by fluorescent
microscopy. Representative images are shown.
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Figure 19. Effect of alcohol on L/R-induced lipid accumulation in mouse primary
hepatocytes. Primary hepatocytes isolated from wild type (WT) or CHOP-/- mice were treated
with L/R coformulation (25μM) without or with ETOH (0, 50, 100 or 200 mM) for 24 h.
Intracellular lipids were stained Oil Red O and detected by microscopy. Representative images
are shown.

72

Figure 20. H&E staining of wild type and CHOP-/- mouse livers with lopinavir/ritonavir
and chronic ethanol feeding. Wild type and CHOP-/- mice were treated with vehicle control
(Sodium Carboxymethyl Cellulose, Na-CMC) or L/R (50 mg/kg), with or without alcohol
(ethanol, 2.5 g/kg) for 8 weeks. The livers were preserved in 3.5% formaldehyde and sectioned
to be stained with H&E. Representative images are shown.
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Effects of alcohol and HIV PIs on the expression of the key genes involved in hepatic
lipid metabolism in primary hepatocytes
The pathogenesis of alcohol- and HIV PI-induced hepatic lipotoxicity develops from a net
result of several factors contributing to progressive hepatic steatosis and eventual apoptotic cell
death. Numerous studies have detailed the metabolism of alcohol and the generation of oxidative
stress damaging the ER, impairing regulation of lipid metabolism, and activation of key
transcription factors that initiate fatty acid production 130. Similarly, our lab has demonstrated that
HIV PIs alter the expression of key genes involved in maintaining lipid homeostasis including
SREBPs and induce hyperlipidemia 116. This study aims to characterize the effect of alcohol on
HIV PI-induced changes of the expression of key genes involved in hepatic lipid homeostasis. As
shown in figure 21, the mRNA levels of SREBP1 and SREBP2 were not significantly changed
after 6-h treatment with L/R with or without alcohol. But, ACC1, the gene that catalyzes the ratelimiting step in de novo fatty acid production, was upregulated by L/R, but not by alcohol.
ApoB100, the major protein component of plasma LDL cholesterol, shows significant
upregulation in response to L/R+ 20 0mM EtOH when compared to the vehicle control DMSO.
To determine the role of CHOP in alcohol and HIV PI-induced dysregulation of the hepatic
lipid metabolism, we examined the mRNA levels of SREBP1, SREBP2, CPT1a, and ACC1 in
mouse primary hepatocytes isolated from wild type and CHOP-/- mice with the same day 6-h
treatment. As shown in figure 22, L/R and ETOH-induced upregulation of SREBP1 and CPT1a
in wild type mouse primary hepatocytes was blocked in CHOP-/- mouse primary hepatocytes.
Significance
Long-term HAART administration has been associated with serious metabolic concerns.
HIV PIs especially been identified as particularly harmful contributing to hepatic and metabolic
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Figure 21. Effect of HIV PIs and alcohol treatment on expression of the key genes in hepatic
lipid metabolism in rat primary hepatocytes. Rat primary hepatocytes were isolated, plated,
treated, and collected for analysis within the same day. Rat primary hepatocytes were treated
with vehicle control (DMSO), or LOPV/RTV (L/R) (25 μM), with or without alcohol (ETOH, 0,
100 0r 200 mM) for 6 h. Total cellular RNA was isolated, and the mRNA levels of the target
genes were quantified by real-time RT-PCR and normalized using internal control GAPDH.
Values are mean ± SE of three independent experiments, which were performed in triplicate.
Statistical significance relative to vehicle control, *p<0.05, and **p<0.01.
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Figure 22. Effect of HIV PIs and alcohol treatment on essential lipid metabolism genes in
wild-type and CHOP-/- primary hepatocytes. Wild-type and CHOP-/- hepatocytes were treated
with vehicle control (DMSO), LOPV/RTV (L/R) (25 μM), and L/R + ethanol (EtOH). Total
cellular RNA was isolated and the mRNA levels of lipid metabolism genes after 6 h treatment
were quantified by real-time RT-PCR and normalized using internal control GAPDH. Values are
mean ± SE of three independent experiments, which were performed in triplicate. Statistical
significance relative to vehicle control, *p<0.05, and **p<0.01.
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damage. Specifically, long-term HIV PI therapies are associated with lipodystrophy
characterized by changes in peripheral body fat mass with lipoatrophy in the face, arms, or legs
and an accumulation of visceral adiposity 131. These changes are especially concerning with the
accumulation of liver fat content and insulin resistance in patients undergoing HIV PI treatment
132

.
The development of metabolic syndrome, obesity, and diabetes results from HIV PI-

induced disruption of lipid metabolism in the liver. Cardiovascular diseases including
atherosclerosis and coronary artery disease are also prevalent as a result of HIV PI treatment 133.
Ritonavir and lopinavir coformulation has been shown to disrupt lipid metabolism and induces
hyperlipidemia in HIV patients 134. Alcohol consumption is also a major concern among
individuals with HIV/AIDS as a risk factor for liver disease. It has been demonstrated that
alcohol triggers intracellular lipid accumulation, fibrosis, and eventual hepatocellular carcinoma.
The molecular mechanisms underlying HIV PI- and alcohol-associated lipotoxicity are yet to be
elucidated. Understanding the cellular mechanisms represents a critical step in the clinical
management of hepatic lipotoxicity and the design of safer drugs in the future.
Our lab has previously demonstrated the effects of HIV PIs on the dysregulation of
hepatic lipid metabolism in hepatocytes and adipocytes by way of activation of ER stress 116, 117.
We hypothesized that as a result of ER stress, HIV PIs and alcohol instigate hepatocyte lipid
accumulation. We also postulated that CHOP is responsible for alcohol- and HIV PI-induced
dysregulation of key genes involved in lipid metabolism in hepatocytes. The fluorescence
imaging data shows an increase in hepatocyte lipid droplet accumulation with alcohol and HIV
PI treatment. Furthermore, a key lipid metabolism regulator SREBP1c was significantly
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upregulated in wild-type hepatocytes treated with alcohol and HIV PIs. However, in CHOP-/hepatocytes, we failed to see upregulation of lipid metabolism genes.
Chapter III: CHOP Deficiency Attenuates HIV PI- and Alcohol-Induced Apoptosis and
Inflammation
Study Rationale
Hepatocytes, the primary parenchymal cells in the liver, are responsible for maintaining
the protein synthesis and degradation balance as well as detoxification functions. Autophagy is a
lysosomal pathway in which intracellular organelles and proteins are degraded as a source of
energy and maintenance of cellular homeostasis. Recently, a role for autophagy has been described
in lipid metabolism as the cell may respond to cytosolic lipid accumulation by sequestering into
autophagosomes that fuse with lysosomes for degradation 135. Impairment of autophagy may result
in the development of dyslipidemia and induce metabolic stress. It also has been shown that ER
stress activation is closely linked with autophagy activation.

However, overactivation of

autophagy will cause cell and tissue injury. Our previous study reported that individual HIV PIs
had a differential effect on the activation of ER stress and the induction of cell death. We are
interested to determine the impact of HIV PI- and alcohol-induced ER stress with CHOP
upregulation on cellular apoptosis and autophagy in murine hepatocytes.
Another cell survival tactic utilized to restore homeostasis and limit tissue injury in
response to pathological stimuli is the activation of the inflammatory cascade. While the liver
primarily functions in metabolic and detoxification activities, the liver participates in an
immunological capacity with the production of acute-phase proteins, cytokines, and chemokines
along with the activation of an array of resident immune cells 136. ER stress as a result of increased
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secretory demand upon exposure to intrinsic and extrinsic factors along with chronic inflammation
are hallmarks of metabolic and liver diseases. It is well documented that alcohol induces liver
inflammation through the polarization and activation of KCs to a pro-inflammatory state. Dr.
Zhou’s lab has previously indicated that HIV PIs induce macrophage NF-κB activation and
proinflammatory cytokine production of TNF-α and IL-6 through ER stress/CHOP mediated
ERK1/2 activation. Moreover, further activation of innate immunity in response to LPS challenge
occurs through macrophage NLRP3 inflammasome activation with production of IL-1β and IL18. Dr. Zhou’s lab has also demonstrated that HIV PIs disrupt intestinal barrier function and
epithelial permeability resulting in increased systemic inflammation.
Results
HIV PIs and alcohol dose-dependently induces apoptosis in rat primary hepatocytes
With proapoptotic transcription factor CHOP, among other ER stress markers,
upregulation by HIV PIs and alcohol, we were interested in examining the degree of apoptosis.
As shown in figure 23, compared to the DMSO vehicle control, rat primary hepatocytes with
alcohol exposure showed slight apoptosis, indicated by Annexin V staining, and a significant
amount of early necrotic cells as indicated by propidium iodide staining. Similarly, hepatocytes
introduced to either ritonavir or lopinavir showed slight apoptosis and significant early necrotic
cells. With the addition of 25 μM alcohol to ritonavir or lopinavir, there is no significant difference
in accumulation of apoptotic cells compared to the HIV PIs alone. With an increased alcohol
concentration of 60 mM in application of ritonavir or lopinavir, there is a significant increase in
the detection of early apoptotic cells compared to alcohol alone. A further increase of alcohol
concentration to 120 mM with HIV PIs advances the degree of apoptotic and necrotic cell detection
matched against the DMSO control + 120 mM treatment group. Figure 24 demonstrates a similar
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pattern with the L/R coformulation and alcohol in wild type mouse hepatocytes. With L/R and
increased alcohol concentration, there is increased staining of apoptotic cells. L/R and alcohol
treatment in CHOP-/- primary mouse hepatocytes showed a muted response in comparison to the
wild type cells.
Alcohol and L/R induces autophagy in rat primary hepatocytes
Autophagy emerges as a protective mechanism against ER stress in targeting misfolded
proteins to maintain proper ER function and cellular homeostasis. Studies describing several
sources of cellular stress including ER stress have linked activation of the UPR and the initiation
of autophagic machinery

137

.

Autophagy genes (ATG) orchestrate the formation of the

autophagosome, a double-membraned structure that delivers intracytoplasmic contents to the
lysosome for degradation

138

. Genes of particular interest include ATG5 and ATG12 which

conjugate, catalyzed by ATG7, to perform autophagosome membrane elongation. We were
interested in investigating the effects of alcohol and HIV PI on key autophagy genes. As seen in
figure 25, ATG5 and ATG12 mRNA were significantly upregulated in the L/R and L/R + 100
mM EtOH treatment groups compared to the DMSO control. There were no significant changes
in ATG7 gene expression with alcohol or HIV PI. We were also interested in mRNA expression
of LC3B, which functions in autophagic selective substrate recruitment into autophagosomes 139.
We found there was no significant LC3B upregulation in response to alcohol and HIV PIs at the
6-hour time-point. Additionally, we considered the effects of CHOP on alcohol and HIV PIinduced autophagy in vitro using wild-type and CHOP-/- mice. The data presented in figure 26
shows L/R + 200 mM EtOH significantly increased mRNA expression of ATG12 in wild-type
hepatocytes, whereas the response in CHOP-/- mouse hepatocytes was attenuated. L/R + 200 mM
EtOH elicited a similar response in elevated ATG5 mRNA expression in wild-type hepatocytes
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yet did not reach significance. These results suggest that CHOP has a role in the autophagic process
in response to ER stress and may mediate the induction of key autophagy genes.
Alcohol and L/R induces a proinflammatory response in hepatocytes and
macrophages
Several studies have suggested the interconnection of the UPR, ER stress, and
inflammation 102, 140, 141. Disruption of intracellular calcium homeostasis and ROS production have
been identified as linking ER stress to the activation of NF-κB and a proinflammatory response 74.
Moreover, ER stress and inflammatory pathways are involved in many chronic metabolic diseases
such as insulin resistance, obesity, and type 2 diabetes

102

. Chronic liver injury results in the

hepatocyte inflammatory cytokine expression through NF-κB and JNK activation ultimately
leading to cell death 142. The activation of immune cells in the liver is mediated by inflammasome
formation in KCs in response to danger signals produced by damaged hepatocytes

143

. Hepatic

macrophages are essential to maintaining homeostasis in the liver with the production of cytokines
and chemokines in response to chronic injury such as alcoholic liver disease 144.
Our lab has previously shown that HIV PIs induce ER stress in intestinal epithelial cells
and disrupt intestinal epithelial barrier integrity increasing the translocation of gut microbiota 145.
These bacterial components are recognized by TLRs on hepatocytes and macrophages and initiate
an inflammatory response. Additionally, we found that HIV PIs activate the UPR in macrophages
and stimulate TNF-α , IL-6 production, and IL-1β suggesting the activation of the inflammasome
112, 146

. The present study characterizes the impact of alcohol and HIV PIs in the activation of

inflammatory pathways. In figure 27, we show the significant upregulation of NF-κB, TNF-α,
and MCP-1 in wild type murine hepatocytes with L/R and 200 mM EtOH treatment. In CHOP-/hepatocytes, the mRNA levels remained elevated in the L/R and 200 mM EtOH treatment group.
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Figure 28 demonstrates significantly increased genetic expression of the inflammasome
component NLRP3 and cytokine production (IL-1β, IL-18) upon stimulation with L/R and 200
mM EtOH. CHOP-/- hepatocytes did now show inflammasome activity in any treatment group.
Our examination of whether alcohol has any effect on HIV PI-induced inflammasome activation
continued with Raw murine macrophages challenged with LPS (50 ng/ml). In Raw macrophages,
L/R alone, and L/R with alcohol (50, 100 mM) showed significant upregulation of NLRP3 mRNA
over 9-fold (Figure 29). Caspase-1, IL-6, TNF-α, IL-18, and TLR mRNA levels upregulation
was dependent on both L/R and alcohol.

IL-1β gene expression with alcohol alone was

comparable to the upregulation seen with alcohol and L/R treatment. This data demonstrates that
alcohol and HIV PI induce macrophage inflammasome activation and inflammatory cytokine
production.
Significance
The development of HIV PIs and incorporation into HAART proved to be a significant
event in the advancement in the management of HIV/AIDS curbing mortality rates. The rendering
of HIV/AIDS into a chronic disease exposed patients to long-term adverse effects experienced by
PI-based antiretroviral treatment. Alcohol misuse by PLWHA may lead to failure to adhere to the
drug regimen, engagement in riskier sexual behavior, and general poor health outcomes 147. Both
alcohol abuse and HAART treatment are well-known contributors to chronic liver disease. Several
cellular pathways are activated as protective mechanisms in either pro-survival or pro-death
responses including UPR activation, inflammation, apoptosis, and autophagy in liver hepatocytes.
Initiation of these pathways as a consequence of chronic ER stress has been implicated in the
pathogenesis of cardiovascular and metabolic diseases 148. Moreover, little is known as to the
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Figure 23. Alcohol and HIV PIs induce apoptosis in primary rat hepatocytes. AnnexinV/Propidium Iodide in Double-staining assay rat primary hepatocytes. Cells were treated with
ritonavir (RTV, 25μM) and lopinavir (LOPV, 25μM) with or without various amounts of alcohol
(25, 60, 120 mM) for 24 hours, and then stained with annexin V-FITC/propidium iodide. The
apoptotic cells were detected with a fluorescent microscope. Green: stained with Annexin VFITC; red stained with propidium iodide.
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Figure 24. Effect of L/R coformulation and alcohol on apoptosis in wild type and CHOP-/murine hepatocytes. Wild type and CHOP-/- mouse primary hepatocytes were treated for 6 hours
with vehicle control (DMSO), LOPV/RTV (L/R) (25 μM), and L/R + ethanol (EtOH). Cells were
treated with lopinavir/ritonavir (25μM) 4:1 with or without various amounts of alcohol (0, 100,
200 mM) for 24 hours, and then stained with annexin V-FITC. The apoptotic cells were detected
with a fluorescent microscope. V-FITC; red stained with propidium iodide.
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Figure 25. Effect of HIV PIs and alcohol on expression of autophagy-associated genes in rat
primary hepatocytes. Rat primary hepatocytes were treated for 6 hours with vehicle control
(DMSO), LOPV/RTV (L/R) (25 μM), and L/R + ethanol (EtOH). Total cellular RNA was isolated
and the mRNA levels of ATG5, ATG7, ATG12, and LC3B were quantified by real-time RT-PCR
and normalized using internal control GAPDH. Values are mean ± SE of three independent
experiments, which were performed in triplicate. Statistical significance relative to vehicle
control, *p<0.05, and **p<0.01.
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Figure 26. Effect of HIV PIs and alcohol on expression of autophagy-associated genes in wildtype and CHOP-/- primary hepatocytes. Wild-type and CHOP-/- primary hepatocytes were
treated for 6 hours with vehicle control (DMSO), LOPV/RTV (L/R) (25 μM), and L/R + ethanol
(EtOH). Total cellular RNA was isolated and the mRNA levels of ATG5, ATG7, ATG12, and
Beclin-1 were quantified by real-time RT-PCR and normalized using internal control GAPDH.
Values are mean ± SE of three independent experiments, which were performed in triplicate.
Statistical significance relative to vehicle control, *p<0.05, **p<0.01, ****p<0.0001.
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Figure 27. Effect of HIV PIs and alcohol on expression of inflammation-associated genes in
wild-type and CHOP-/- primary hepatocytes. Wild-type and CHOP-/- primary hepatocytes were
treated for 6 hours with vehicle control (DMSO), LOPV/RTV (L/R) (25 μM), and L/R + ethanol
(EtOH). Total cellular RNA was isolated and the mRNA levels of NFκB, TLR4, MCP-1, and TNFα were quantified by real-time RT-PCR and normalized using internal control GAPDH. Values
are mean ± SE of three independent experiments, which were performed in triplicate. Statistical
significance relative to vehicle control, *p<0.05, **p<0.01, ***p<0.001.
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Figure 28. Effect of HIV PIs and alcohol on expression of inflammasome activation in wildtype and CHOP-/- primary hepatocytes. Wild-type and CHOP-/- primary hepatocytes were
treated for 6 hours with vehicle control (DMSO), LOPV/RTV (L/R) (25 μM), and L/R + ethanol
(EtOH). Total cellular RNA was isolated and the mRNA levels of NLRP3, IL-1β, and IL-18 were
quantified by real-time RT-PCR and normalized using internal control GAPDH. Values are mean
± SE of three independent experiments, which were performed in triplicate. Statistical significance
relative to vehicle control, *p<0.05, **p<0.01, ***p<0.001.
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Figure 29. Effect of HIV PIs and alcohol on expression of inflammasome activation in RAW
cells. Raw 264.7 murine macrophage cells were treated for 6 hours with vehicle control (DMSO),
LOPV/RTV (L/R) (25 μM), and L/R + ethanol (EtOH- 50, 100 mM). Total cellular RNA was
isolated and the mRNA levels of NLRP3, Caspase-1, IL-1β, IL-6, IL-18, TNF-α, and TLR4 were
quantified by real-time RT-PCR and normalized using internal control GAPDH. Values are mean
± SE of three independent experiments, which were performed in triplicate. Statistical significance
relative to vehicle control, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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mechanisms defining the interplay of the pathways as autophagy and apoptosis have been shown
to integrate and work in concert and disconcert with mutual regulation.
CHOP is well established as a proapoptotic factor downstream of UPR signaling pathways
induced under ER stress conditions instigating hepatocellular apoptosis 95. Hepatic apoptosis is a
feature of alcoholic liver disease as a result of chronic intracellular stress. Similarly, ER stress is
linked to inflammation with downstream activation of NF-κB and translocation to the nucleus
triggering upregulation of pro-inflammatory cytokines and chemokines 102. CHOP has also been
shown to perform in a regulatory capacity and enhance the expression of pro-inflammatory
mediators 76. Autophagy is induced under ER stress conditions following failure of the proteasome
to restore cellular homeostasis. Studies have shown that autophagy may sensitize cells to apoptosis
in a CHOP-dependent manner 149.
Dr. Zhou’s lab has previously shown the effects of HIV PIs ritonavir and lopinavir and
increased apoptosis in wild type mice but not in CHOP-/- mice suggesting that CHOP is an
essential molecular link of ER stress and hepatotoxicity 111. Additionally, under ER stress
conditions, it has been demonstrated that HIV PIs effectively stimulate the production of proinflammatory cytokines in macrophages CHOP-mediated intracellular signaling 150. Similarly,
our lab has shown autophagy activation as a response to ritonavir and lopinavir in mouse and
human adipocytes 117. The present study shows alcohol and HIV PI trigger upregulation of NFκB and proinflammatory cytokines, chemokines, and inflammasome components in hepatocytes
and macrophages. We also showed increased expression of apoptosis-related genes with HIV PI
and alcohol treatment.
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DISCUSSION
HIV PI- and alcohol-induced ER stress in hepatocytes
The introduction of the HARRT regimen has proven to be a clinically effective treatment
for HIV/AIDS since its introduction in 1996. The introduction of pharmacological agents targeting
different stages of the HIV life-cycle ushered in a new era of HIV treatment improving patient
outcomes by reduction of viral loads, decrease in the incidence of opportunistic infections, and
halting the steep decline of the CD4 cell population. Continued long-term HAART treatment may
effectively bring the viral load to undetectable levels curtailing a deadly disease yet considerations
must be made for the side effects associated with HAART over life-span of the patient. DILI is a
major concern as it often leads to interruption or discontinuation of therapeutics in favor of quality
of life. DILI may present in a low-grade impact with elevated liver enzymes or acute liver injury
with hepatocellular apoptosis and necrosis as a dominant feature. Anti-HIV drugs are especially
toxic and significantly increase the serum levels of liver enzymes. HAART with HIV PI
incorporation is the most common treatment and is associated with hepatotoxicity and underlying
liver disease complicated by other drugs neutralized by the liver. HIV PIs disrupt hepatocyte lipid
homeostasis, gluconeogenesis, and bile acid synthesis through chronic ER stress leading to the
development of cardiovascular complications and metabolic syndrome. Alcohol abuse is a
comorbid risk factor for hepatotoxicity with HAART administration with the avoidance of alcohol
significantly reducing hepatic injury

151

. As the liver is responsible for metabolizing alcohol,

alcoholic liver injury is a common yet preventable occurrence. Alcohol related mortality is a
leading cause of death worldwide with ALD accounting for a large proportion illustrating a major
public health problem. ALD pathogenesis begins with steatosis, which is reversible with alcohol
discontinuation and progresses to stages of inflammation, fibrosis, and liver cancer.
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An upregulation of ER stress component has been identified in the pathogenesis of alcohol-induced
liver disease.

Hepatocytes attempt to circumvent the metabolic and inflammatory stresses

manifested by HIV PI- and alcohol-induced ER stress by activating apoptotic/necrotic and
autophagy mechanisms.
Our working hypothesis is that HIV PIs and alcohol provoke liver injury by activation of
hepatocyte ER stress and CHOP upregulation disrupting lipid metabolism and instigating
production of proinflammatory factors resulting in dyslipidemia, fatty liver, and lipotoxicity. We
project the lipotoxic effects of HIV PIs and alcohol to be remediated in CHOP-/- models.
Our lab has previously described the role of ER stress in HIV PI-induced hepatic steatosis
and liver injury. Ritonavir was shown to be a potent inducer of the UPR activation and ER stress
in macrophage cell lines and primary mouse peritoneal macrophages 112. Similarly, our lab
showed ritonavir activation of the UPR and apoptosis of hepatocytes 116. Moreover, a role was
identified for CHOP as an important molecular link of ER stress and hepatotoxicity. CHOP-/mice showed a significant reduction in liver injury as compared to wild-type mice challenged
with ritonavir or lopinavir. As ritonavir is used as a pharmacokinetic enhancer for lopinavir, we
investigated the lopinavir/ritonavir coformulation with alcohol in ER stress induction.
The role of ER stress and CHOP in dysregulation of lipid metabolism
The ER is responsible for the regulation of critical metabolic homeostasis including lipid
metabolism, protein synthesis, and gluconeogenesis. Lipid metabolism is of particular
importance as a public health concern has been clinically identified with a significant increase in
the prevalence of metabolic syndrome over the last couple decades. Dietary factors influence the
progression of pathological conditions of metabolic syndrome including hyperglycemia,
hypercholesterolemia, dyslipidemia, insulin resistance, type 2 diabetes, and central obesity.
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Figure 30. Model of HIV PI- and alcohol-induced hepatotoxicity. Our working hypothesis
suggests dual HIV PI and alcohol lipotoxic and inflammatory effects.
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Specifically, the Western diet has been linked to poor health implications with a high
glycemic load, excessive fatty acid composition, and accumulation of lipids in the liver 152.
Similarly, alcohol consumption manipulates intracellular mechanisms leading to hepatic
steatosis, inflammation, and the development of AFLD.
Numerous studies have elucidated a role of ER stress in the pathogenesis of AFLD.
Alcohol, by way of the metabolite acetaldehyde toxicity or CYP2E1-induced oxidative stress, is
one of several pathological stimuli capable of disrupting intracellular homeostasis causing
accumulation of misfolded proteins resulting in UPR activation and downstream induction of
SREBP. Ji et al. demonstrated in an intragastric alcohol-fed mice model that fatty liver
development was associated with increased GRP78, CHOP, and SREBP-1 gene expression 153.
Transgenic mice with SREPB-1 overexpression display severe hepatic steatosis and
hepatomegaly 154. Conversely, intragastric-alcohol delivery in SREBP1-c null mice shows
reduced liver triglycerides than the wild-type littermates 155. The advent and adoption of
HAART revealed the adverse effects of PIs including dyslipidemia and hepatic steatosis
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.

Previous studies from Dr. Zhou’s lab have outlined the effects of HIV PI-induced ER stress on
hepatic lipotoxicity. Ritonavir was shown to activate the UPR, upregulate SREBPs, and increase
apoptosis of macrophages 112. A role for CHOP was elucidated with CHOP-/- mice showing a
significant reduction in hepatic triglyceride accumulation, liver injury, and inflammation
compared with wild-type littermates upon ritonavir and lopinavir treatment independently 111.
HIV PI- and alcohol-induced ER stress and Induction of Apoptosis
Under conditions of ER stress due to several pathological insults (including alcohol and
saturated fatty acids), the UPR is activated to respond and restore ER homeostasis while failure to
do so ultimately triggers cell death mechanisms. CHOP has been shown to be an important
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mediator of ER stress related hepatocyte apoptosis as indicated by CHOP knockdown studies 156.
Apoptosis commences through either the extrinsic or the intrinsic pathway with both leading to
recruitment and activation of caspases. The extrinsic pathway of apoptosis begins with ligand
binding of either of the three death receptors in the liver including the Fas receptor, tumor necrosis
factor-α receptor (TNFR), and TNF-related apoptosis inducing ligand (TRAIL).

All death

receptors are ubiquitously expressed in the liver and upon activation recruit adapter proteins
containing a death domain that associates with initiator caspases 8 and 10 completing the formation
of the death-interacting signaling complex (DISC)

157

. Caspase 8 and 10 are cleaved to their

functional states upon formation of the DISC and triggers a caspase activation cascade with
effector caspases 3, 6, and 7 activated. The activation of effector caspases are able to initiate
apoptosis in type I cells (lymphocytes), however, type II cells (hepatocytes) are unable to produce
sufficient caspase 8 levels and require release of mitochondrial proapoptotic Bcl-2 proteins that
are upregulated in disease states 157. Caspase 8 utilizes the cytosolic protein Bid as a substrate to
activate Bcl-2 proteins Bax and Bak to serve as mediators of mitochondrial outer membrane
permeabilization (MOMP) 158. Under normal conditions, another division of Bcl-2 proteins found
in the mitochondria and the ER membrane that are anti-apoptotic bind with Bax and Bak and
inhibit MOMP. Studies have elucidated the role of Bid showing hepatocyte apoptosis and liver
injury is attenuated in Bid-deficient mice following Fas receptor stimulation 159. In hepatocytes,
MOMP and release of cytochrome c into the cytosol where it binds to the apoptosome facilitates
effector caspase induction of the apoptotic cascade.
The intrinsic pathway of apoptosis is provoked by intracellular agonists including oxidative
and ER stress and operates similarly as the extrinsic pathway. During ER stress conditions, the
tumor suppressor p53 translocates to the mitochondria and functions as a transcription factor and
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activates apoptosis by upregulating proapoptotic Bak, Bax, Bid, Bim, Noxa, and Puma

160

. ER

stress and elevated CHOP expression has been demonstrated to increase levels of Bim and Bax
and decreases Bcl-2 prosurvival proteins 60. ER stress mediated Bax upregulation also triggers the
release of ER calcium through increasing inositol 1,2,3-triphosphate receptor activity stimulating
caspase activation and cytochrome c release

161, 162

. A role has been identified for CHOP in

transcriptional activation of proapoptotic proteins and death receptors in fatty acid-treated
hepatocytes

163, 164

. In alcohol-fed CHOP-deficient mice, there is significant upregulation of

Gadd45, cathepsin B, fatty liver and ER stress evidenced by Grp78, yet there is an attenuation of
hepatocellular apoptosis identifying CHOP as essential for tipping the balance of the cell from
survival toward apoptosis 49.
HIV PI- and alcohol-induced ER stress and Induction of Autophagy
Cells respond to their environmental stressors by continuously engaging adaptive
mechanisms to survive and regain homeostasis. Numerous studies have indicated ER stress can
induce either apoptosis or autophagy and crosstalk exists among the pathways with mutual
inhibition. Autophagy serves as an alternative response to cellular stress that spares the cell from
self-destruction. Studies illustrated that autophagy pathways are triggered in the absence of Bcl-2
proapoptotic Bax and Bak 165. The prosurvival nature of autophagy is shown in that inhibition of
ATG5 or ATG7 in Bax- and Bak-deficient cells still resulted in cell death 166. The UPR renders
IRE1 and ATF6 activation and splicing of XBP1 to its active form to translocate to the nucleus
where it acts as a transcription factor for several genes including autophagy through Beclin-1 167.
Additionally, activation of the PERK pathway results in ATF4 translocation to the nucleus and
upregulates ATG12, while ATF4-mediated CHOP activation is able to induce ATG5

168

.

Autophagy protects the cell from accumulated misfolded proteins and lipids by capturing into a
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double-membraned autophagosome for transportation to the lysosome for degradation. With liver
steatosis being an early stage of fatty liver disease, an autophagic response to lipid accumulation
is an important pro-survival mechanism during unmitigated ER stress. Autophagy was long
believed to be a bulk, nonselective process, yet recent evidence suggests selective sequestration
and elimination of cargo

169

.

Lipophagy serves as an alternate pathway for lipid droplet

degradation with removal by autophagosome capture and fusion with lysosomes where enzymatic
action reduces lipids to glycerol and fatty acids 170.
Lipophagy has been revealed as a critical method of cellular lipid removal in several cell
types including hepatocytes and impairment is linked to steatohepatitis, atherosclerosis, and
metabolic syndrome

171

.

In vitro studies with cultured hepatocytes have shown autophagy

induction to regulate intracellular lipid stores following acute fatty acid exposure 172. Conversely,
in vivo studies revealed pronounced hepatomegaly and significant increased lipid accumulation in
liver-specific ATG7-/- mice

172

. The regulation of the selectivity of lipophagy and other cargo

specific autophagic pathways has yet to be mechanistically defined. Ding et al. demonstrated the
pharmacological agents enhancement of lipophagy attenuating ethanol-induced steatosis and
hepatotoxicity by reducing CYP2E1-related ROS production and mTOR inhibition with in vivo
mouse models 173. Contrastingly, autophagy inhibition by blocking autophagosome formation by
3-metyhladenine inhibition of PI3K and mTOR activation resulted in enhanced caspase activation,
hepatocyte apoptosis, and liver injury 173. Thus, we hypothesize that modulation of the autophagic
pathway may potentially serve as a viable therapeutic option to ameliorate HIV PI- and alcoholinduced fatty liver disease.

Compounding the effects of hepatic steatosis, suppression of

autophagy may further exacerbate ER stress, insulin resistance, and instigate hepatic inflammation
174

.
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HIV PI- and alcohol-induced inflammation
Chronic ER stress, a symptom of liver injury, cardiovascular and metabolic diseases,
activates inflammatory cascades as an adaptive defense mechanism for cell survival. While
convention designates the liver as a nonimmunological organ, the liver participates in many
immunological functions mediated by a diverse immune cell repertoire 136. The liver receives
blood supply directly from the gut via the portal vein supplemented with dietary antigens along
with gut microflora and must exercise tolerance yet maintain immunosurveillance for pathogenic
infections 136. Hepatocytes are directly exposed to the blood as it circulates though the hepatic
sinusoids to the central vein facilitating the exchange of molecules that require hepatocyte action.
Inflammation is potentially an important determinant of susceptibility to HIV PI- and alcoholinduced ER stress-mediated hepatotoxicity.
PRR expressed on hepatocytes and KCs bind to PAMPs inducing phagocytosis and
degradation fostering pathogen clearance and immune regulation. Hepatocytes respond to
PAMPs by the secretion of complement proteins to opsonize the target molecule phagocytosis.
Liver homeostasis following tissue injury is also managed by hepatocyte activation of the acute
phase response, serum amyloid a production, and acute inflammation after proinflammatory
cytokines IL-6, IL-1β, and TNF-α activation of STAT3 and NF-κB. SAA is specific to Gramnegative bacteria, LPS, and stimulates macrophage secretion of IL-6 and TNF-α. Tajiri et al.
showed elevated levels of TNF-α and IL-6 in individuals with insulin resistance and diabetes 175.
Similarly, increased TNF-α expression in adipose tissue potentiates human obesity and insulin
resistance 176. Transgenic mice allowing constitutive low-level liver NF-κB expression show a
type II diabetes phenotype characterized by hyperglycemia, insulin resistance, and hepatic IL-6,
IL-1β, and TNF- α production 177. Hepatocytes are also potent recruiters of innate immune cells.
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Hepatocyte secretion of monocyte chemoattractant protein-1 (MCP-1) to attract infiltrating
monocytes/macrophages is exhibited in AFLD 120. Other cell populations are expanded under
episodes of chronic liver disease including dendritic cells, myeloid-derived suppressor cells,
natural killer cells, NK T cells, and hepatic stellate cells 136.
All three branches of the UPR are able to initiate proinflammatory transcriptional
programs through activation of NF-κB. Alternatively, the PERK pathway also uses ATF4 to
carry out immunomodulatory functions by upregulation of CHOP expression and subsequent
downstream upregulation of IL-23 178. CHOP upregulation has been linked to NLRP3
inflammasome activation and hepatocyte cell death 81. Accumulating evidence in metabolic
disease states provides insight into the ER stress-induced inflammasome activation. NF-κB
mediates NLRP3 inflammasome expression in cultured hepatocytes upon LPS stimulation 179.
Cholesterol crystals, a hallmark of atherosclerosis, are necessary for NLRP3 inflammasome and
caspase-1 activation 180. Confirming the role of the inflammasome, LDLR-deficient mice
reconstituted with NLRP3-deficient bone marrow and fed a high cholesterol displayed a
suppression of atherosclerosis development marked by decreased inflammasome-dependent
cytokine production 180. Researchers have identified the importance of inflammasome IL-1β in
several diseases. IL-1β is capable of initiating a robust neutrophilic inflammatory response in
response to bacterial infections. A role has also been identified in type 2 diabetes where high
glucose yields elevated IL-1β causing an impairment of insulin secretion, chronic
hyperglycemia, and ultimately leading to pancreatic β-islet cell death 181. IL-1β produced by
macrophages is crucial to formation of foam cells that enter the arterial wall and manipulate the
inflammatory plaque formation of atherosclerotic lesions 182. In vitro and in vivo studies have
revealed an increase in macrophage IL-1β production in the postprandial state induced by
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cholesterol, chylomicrons, or triglycerides 182. Elevated serum levels of IL-18 has been shown to
be of predictive indicator of cardiovascular events, liver steatosis, and hepatocyte injury 183, 184.
In review of our study, considerations must be made for limitations in the experimental
design. A noteworthy distinction is the usage of the global CHOP-/- mice model rather than a
tissue-specific conditional knockout mouse model. A conditional knockout is accomplished by
inactivation of the target gene through floxing (flanked by loxP sites) an essential exon and
breeding with Cre expressing transgenic animals with a cell type specific promoter 185. The
resulting progeny with target gene tissue-specific conditional knockouts can be identified by
genotyping. Previous studies have indicated hepatic conditional knockout of UPR elements
resulting in a failure to attenuate ER stress and exacerbation of metabolic damage 186, 187. We
anticipate a liver-specific CHOP-/- mouse model would offer similar protection from hepatic
lipotoxicity as seen in the current study.
Another concern of our experimental design is the lack of review of the consequences of
HIV PI and alcohol administration on extrahepatic tissues. Particularly, our lab has previously
demonstrated that HIV PIs activate ER stress and disrupt lipid metabolism in adipocytes
contributing to metabolic complications 117. We project alcohol would exacerbate HIV PIassociated toxic side effects in adipose tissue. Additionally, reflection on the experimental
design brought out the neglect to address the interplay of hepatocytes and liver KCs in alcoholand HIV PI-induced lipotoxicity. Although we described production of proinflammatory
cytokines and activation of the inflammasome in a macrophage cell line, further insight would be
obtained with KCs. Specifically, with the utilization of hepatocyte and KC co-culture systems,
the effect of KC direct interaction with hepatocytes and/or KC inflammasome activation and
proinflammatory cytokine production on the alcohol- and HIV PI-induced lipotoxicity can be
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determined. Another issue with the present study is the restriction to rodent models and lack of
human data. Furthermore, our experimental design fails to account for the increased risk of DILI
in HIV coinfected patients.
CONCLUSSION
In summary, the current study shows that HIV PIs and alcohol provoke liver injury by
activation of hepatocyte ER stress and CHOP upregulation disrupting lipid metabolism and
instigating production of proinflammatory factors resulting in dyslipidemia, fatty liver, and
lipotoxicity (Figure 30). We project the lipotoxic effects of HIV PIs and alcohol to be remediated
in CHOP-/- models (Figure 30).

While alcohol has been linked to HAART-associated

hepatotoxicity, the underlying mechanisms behind the poor outcomes in HIV-infected patients
remain to be identified. Further understanding of the cellular mechanisms of alcohol- and HIV PIinduced hepatic lipotoxicity may lead to new therapeutic strategies and the development of new
drug treatments.
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